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Ovarian cancer is the leading cause of reproductive cancer death in U.S. women.  This 
high mortality rate is due, in part, to the lack of early detection methods and 
incomplete understanding of the origin of the disease.  Animal models of ovarian 
cancer can shed light on the genetic and biological factors that influence tumor 
development and/or progression, as well as identify strategies for prevention, early 
detection and treatment.  One animal model, the domestic hen, has a high spontaneous 
incidence of the disease that is age-dependent, similar to women.   Although previous 
studies utilizing the hen as a model for ovarian cancer have characterized chicken 
ovarian tumors and tested putative prevention and treatment strategies of the disease, 
our understanding of the development and progression of ovarian cancer in the hen is 
still limited.  Our objectives were 1) to further characterize chicken ovarian tumors 
through global gene expression analysis; 2) to test the effect of progestin and estrogen 
together, as commonly delivered in “the pill”, as well as progestin and estrogen alone 
on ovarian cancer prevalence in the hen; and 3) to determine estrogen receptor subtype 
expression in chicken ovarian tumors.  The second and third objectives were based on 
evidence in women that steroid hormones play a role in ovarian cancer, with estrogen 
associated with an increased risk and progesterone associated with a decreased risk of 
the disease.  We have shown that administration of “the pill” is associated with a 
significant decrease in ovarian cancer prevalence, as well as egg production, 
 suggesting that ovulation is important for the initiation of ovarian cancer.  
Furthermore, we observed that chicken ovarian tumors over-express oviduct-related 
genes, even at early stages, providing evidence that tumors possibly arise from the 
epithelial cells of the oviduct.  Finally, our results also support a role for steroid 
hormones, particularly estrogen, in mediating ovarian tumor progression. Collectively, 
our studies have provided information regarding the development and progression of 
ovarian cancer in the hen that may help unlock the mysteries of the disease in women.    
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CHAPTER 1 
LITERATURE REVIEW 
Ovarian cancer 
Ovarian cancer has a high mortality rate 
Ovarian cancer is broadly defined as cancer that forms in tissues of the ovary.  
It has been estimated that, in 2010, approximately 22,000 women will be diagnosed 
with ovarian cancer and more than 13,800 women will die of the disease [1].  Ovarian 
cancer is the leading cause of reproductive cancer death in the U.S [2].  This high 
mortality rate can be attributed to the fact that greater than 80% of women are 
diagnosed once the cancer has metastasized and the 5-year survival rate is less than 
30% [3].  The 5-year survival rate is similar for the approximately 7% of women with 
unknown stage at diagnosis [3].  In contrast, the 5-year survival rate is greater than 
90% for the approximately 15% of women diagnosed with cancer localized to the 
ovary [3]. 
Detection strategies for ovarian cancer are ineffective 
These statistics highlight the importance of early detection of ovarian cancer; 
however, efforts to identify a widely acceptable screening strategy have thus far failed.  
One obstacle to early detection is the vagueness of symptoms experienced by women 
with the disease.  These symptoms include pressure or pain of the back or abdomen, 
fatigue, bloating, constipation and urinary problems.  Although these symptoms are 
not specific to ovarian cancer, their severity and frequency may indicate the presence 
of benign and malignant ovarian masses [4].  Current methods of screening and 
detecting ovarian cancer include physical and pelvic exams, blood tests, ultrasound 
and biopsy.  Physical and pelvic exams can determine whether there is abnormal 
accumulation of fluid in the abdomen (ascites) and the size and shape of the ovaries 
and surrounding organs, respectively.  Transvaginal ultrasound (TVS) can also be used 
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to detect abnormalities in ovarian size and shape, but this technique suffers from poor 
sensitivity [5].  Blood tests can also be conducted and the most widely used serum 
marker is CA125.  Elevated levels of CA125 are found in >80% of patients with 
ovarian cancer, but are also associated with benign gynecological and non-
gynecological diseases [6].  CA125 has proven a useful marker to monitor disease 
status and is one of two serum biomarkers approved by the FDA for this purpose, 
along with human epididymis protein 4 (HE4) [7].  For cancer detection, levels of 
these markers can be determined alone, although sensitivity may be increased when 
multiple markers are assessed together [7], or in combination with TVS [5].  Based on 
the results of these tests, a doctor may recommend surgery to obtain a biopsy to 
confirm the diagnosis.  Unfortunately, these detection methods are better suited for 
detecting late stage disease, once the tumor is large enough for physical detection (if 
confined to the ovary), has spread beyond the ovary, or is producing large enough 
quantities of serum biomarkers suitable for detection in the blood. 
Ovarian tumor stage and grade determine course of treatment  
Ovarian cancer is a surgically staged disease and tumors are staged according 
to the criteria set by the International Federation of Gynecology and Obstetrics 
(FIGO).  These criteria are similar to the American Joint Committee on Cancer 
(AJCC)/TNM system that describes the extent of the primary tumor (T), absence or 
presence of metastasis to lymph nodes (N), and absence or presence of metastasis to 
distant sites (M) [2].   Stage I is the least advanced stage with the cancer still confined 
to the ovary (ovaries).  In stage II cancer, the tumor is in one or both ovaries and has 
spread to other organs in the pelvis (i.e. uterus, fallopian tubes, etc.).  A woman is 
diagnosed with stage III cancer if the cancer is in one or both ovaries and has spread 
beyond the pelvis to the lining of the abdomen and/or the lymph nodes.  Stage IV is 
the most advanced stage of ovarian cancer where the cancer has spread to organs 
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outside of the peritoneal cavity, including the liver and the lungs.  Ovarian tumors are 
also graded depending on tissue morphology and how likely it is that the cancer will 
spread.  Grade 1 tumors are well-differentiated (look like normal ovarian tissue) and 
less likely to spread.  Grade 2 tumors are not as well-differentiated compared to grade 
1.  Grade 3 tumors are poorly-differentiated (do not look like ovarian tissue) and are 
more likely to spread.  Accurate staging and grading of ovarian tumors is important in 
order to determine the best course of treatment. 
Current treatment options for women with ovarian cancer include surgery and 
chemotherapy.  There are two main goals of surgery for ovarian cancer: staging (as 
mentioned previously) and debulking (the removal of as much tumor tissue as 
possible) [2].  Patients who have undergone successful debulking have a more 
favorable prognosis than those left with larger tumors after surgery [8].  Surgery is 
generally followed by chemotherapy (the use of chemicals to treat disease).  This form 
of treatment is generally systemic and specifically targets cancer cells that are rapidly 
dividing.  There are frequently side effects, however, since normal cells that have 
similar characteristics (i.e. epithelial lining of the stomach and hair follicles) may also 
be damaged resulting in nausea, vomiting, and loss of hair.  Common chemotherapy 
regimens for ovarian cancer include combination therapy with a platinum compound, 
such as carboplatin or cisplatin, and a taxane, such as paclitaxel [8].  Although patients 
with advanced disease will initially respond to chemotherapeutic regimens, a large 
proportion (50%) will have recurrent disease and overall poor survival [8].  The initial 
treatment for women with stage I disease is surgery to remove the tumor.  In these 
women, chemotherapy is recommended if the tumor is high grade [2].  For stage II , 
III and IV cancer, treatment starts with debulking surgery followed by chemotherapy 
and may include removal of the uterus, fallopian tubes, ovaries and omentum (stage III 
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and IV) as well as successive rounds of surgery and chemotherapy to improve quality 
of life (stage IV).   
Ovarian cancer is a heterogenous disease comprised of different types of cancers 
Ovarian cancer is a heterogenous disease that includes several types of cancer 
with different etiologies, pathologies and responses to treatment.  There are three main 
types of ovarian tumors: epithelial, germ cell and sex cord stromal.  Epithelial ovarian 
tumors are the most common type of ovarian cancer in women (90%) [9], and are 
thought to be derived from the cells that cover the outer surface of the ovary (ovarian 
surface epithelial cells; OSE).  Germ cell tumors account for ~4% of ovarian cancer 
cases [9] and originate from the cells that produce the ova (eggs).  Sex cord-stromal 
tumors account for about 6% of ovarian tumors [9] and are derived from the stromal 
cells in the connective tissue of the ovary and produce estrogen and testosterone.  
Since epithelial ovarian tumors are the most common, further discussion will focus on 
this type. 
Epithelial ovarian tumors can be further divided into 4 subtypes: serous, 
endometrioid, mucinous and clear cell [10].  This classification is based on the 
predominant pattern of differentiation of tumor cells.  The prevalence of these 
subtypes varies in the literature, but serous epithelial ovarian tumors are by far the 
most common.  Serous tumors resemble fallopian tube epithelium and have a 
prevalence of 80-85% [11].  In general, serous tumors can display a broad spectrum of 
characteristics including glands, solid sheets of cells, or slit-like spaces [10].  
Endometrioid ovarian tumors resemble endometrial glands and account for about 10% 
of epithelial ovarian tumors [11, 12].  These tumors are characterized by distinctive 
glands lined by columnar cells with large, atypical nuclei and basophilic cytoplasm 
[10].  Mucinous ovarian tumors can resemble either endocervical or intestinal 
epithelium and have a prevalence of about 3% [11, 12].  These tumors are composed 
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of irregular cysts and glands lined by atypical mucinous cells [10].  Clear cell ovarian 
tumors resemble uterine epithelial cells and accounts for approximately 5-13% of all 
ovarian tumors [11, 12].  These tumors are characterized by clear cells containing 
abundant cytoplasmic glycogen and peg-shaped (hobnail) cells [10].  Less common 
types of ovarian tumors include Brenner, undifferentiated, and mixed epithelial 
tumors.   
Risk factors for ovarian cancer include family history, reproductive factors, and 
environmental factors 
Epidemiological studies have identified risk factors associated with the 
development of epithelial ovarian cancer.  The most significant risk factor is a family 
history of the disease, which accounts for approximately 5-10% of ovarian cancers [8].  
Mutations of the breast cancer type 1 protein (BRCA1) and breast cancer type 2 
protein (BRCA2), explain approximately 90% of hereditary ovarian cancer cases [13], 
with the lifetime risk for ovarian cancer being 30-40% and 27% for women carrying 
the BRCA1 or BRCA2 mutation, respectively [8].  Ovarian cancer is also strongly 
associated with hereditary nonpolyposis colorectal cancer (HNPCC) syndrome (also 
known as Lynch II syndrome), characterized by mutations in DNA mismatch repair 
genes, including MSH2, MLH1, PMS1, and PMS2 [14].  The risk for ovarian cancer 
for women with this syndrome is 10% [8].   
Reproductive factors are also associated with risk of ovarian cancer with 
nulliparity, infertility, and late menopause increasing risk and multiparity and lactation 
decreasing risk [13].  Exogenous hormones contribute to the associated risk of ovarian 
cancer and the role of steroid hormones in ovarian cancer development and/or 
progression will be discussed later in further detail.  Briefly, hormone replacement 
therapy (HRT) is associated with an increased risk and oral contraceptive use is 
associated with a decreased risk [13].  Gynecologic-related conditions such as 
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endometriosis and polycystic ovarian syndrome (PCOS) are associated with increased 
risk, while tubal ligation and hysterectomy are associated with decreased risk [13].  
Environmental factors possibly associated with increased risk of the disease are use of 
talcum powder, cigarette smoking, and obesity, while consumption of fruits and 
vegetables, green and black tea, and dietary vitamin D are associated with decreased 
risk [13].  Future studies are needed to confirm the association between these 
environmental factors and risk of ovarian cancer. 
The numerous hypotheses proposed to explain the development of ovarian cancer 
highlight the complexity of the disease 
Based on the epidemiological evidence, several theories have been proposed to 
explain the development of ovarian cancer.  These are the incessant ovulation, 
inflammation, gonadotropin, and hormonal hypotheses.  The incessant ovulation 
hypothesis proposes that the repeated rupture and repair of the ovarian surface 
epithelium (OSE) during ovulation predisposes the OSE to genetic mutations that 
could lead to development of ovarian cancer [15].  Related to the incessant ovulation 
hypothesis is the inflammation hypothesis.  The process of ovulation resembles an 
inflammatory reaction and it is thought that inflammatory factors produced may lead 
to genetic mutations in OSE that could result in ovarian cancer development [16].  The 
gonadotropin hypothesis postulates that elevated levels of gonadtotropins, related to 
the preovulatory surge and loss of negative feedback during menopause, play a role in 
the development and progression of ovarian cancer [17].  Finally, hormones are also 
thought to play a role in ovarian cancer development with androgens and estrogens 
promoting cancer formation, and progesterone inhibiting cancer formation [18].  The 
hormonal hypothesis will be discussed later in further detail.  These hypotheses are not 
mutually exclusive and it is likely that a combination of factors determines 
development of ovarian cancer.  For example, pregnancy is associated with a 
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decreased risk of ovarian cancer accompanied by a decrease in ovulatory events and 
exposure to gonadtotropins, as well as elevated progesterone levels.  Thus, pregnancy 
supports the incessant ovulation, gonadotropin and hormonal hypotheses, highlighting 
the complexity of ovarian cancer development. 
Alternative sites of origin of ovarian cancer, aside from the OSE, have been proposed 
Historically, the OSE is believed to be the source of the majority of epithelial 
ovarian tumors in women.  The OSE is the mesothelium that covers the ovary and 
consists of a single layer of flat-to-cuboidal epithelial cells which are separated by a 
basement membrane from an underlying stroma (tunica albuginea) that is comprised 
of collagenous connective tissue [19].  Normal OSE cells in the adult express both 
epithelial and mesenchymal markers and exhibit phenotypic plasticity, especially 
during post-ovulatory repair [20].  Studies have shown that the OSE shares some 
properties of relatively uncommitted pleuripotent cells, including the ability to 
proliferate, undergo morphological changes in response to environmental stimuli, and 
differentiate along several pathways [19].  These characteristics are believed to be 
responsible for the propensity of the OSE to undergo neoplastic transformation.  
Neoplastic transformation results in the acquisition of characteristics of Müllerian 
epithelial phenotypes, including characteristics of the fallopian tube, endometrium, 
endocervix, and vagina for the serous, endometrioid, mucinous and clear subtypes, 
respectively.   
During ovulation, OSE cells proliferate and migrate to heal the ovulatory 
wound and may become trapped in the ovarian stroma where they form inclusion cysts 
(the preferred site of neoplastic progression).  Inclusion cysts are not only related to 
ovulation, but may also form from invaginations of the OSE that become more 
common as the ovary ages [19] or due to inflammation and/or stromal-epithelial 
interactions [21].  Evidence that OSE and its cystic derivatives are sites of origin of 
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ovarian cancer rests on the fact that both OSE and inclusion cysts can differentiate into 
Müllerian epithelium and are sites of precancerous lesions and small carcinomas [21].  
Studies have shown an increased incidence of ovarian cysts in the contralateral ovary 
from cancer patients [22], suggesting that these inclusion cysts represent early stages 
of neoplastic progression.  It should be noted, however, that inclusion cyst formation 
can be increased in mice, with no observed progression to cancer [23, 24]. 
Some evidence has cast doubt on the idea that the OSE is the site of origin of 
all epithelial ovarian tumors.  For one thing, ovarian epithelial tumors are similar to 
epithelial cells from other sites of the reproductive tract, not the ovary [25].  In fact, 
one study reported that the patterns of gene expression in different subtypes of ovarian 
cancer correlate with those in their normal Müllerian derived counterparts (i.e. 
fallopian tube, endometrium, etc.) and not OSE [26].  Furthermore, Cheng et al 
observed that the ovarian tumor subtypes expressed the same set of HOX genes as the 
epithelial cells of their normal Müllerian-derived counterparts [27].  HOX genes are 
highly specific for the different segments of the reproductive tract, supporting the idea 
of an alternative site of origin.  Studies have also shown that paired box 2 (PAX2), a 
gene required for Müllerian duct development, is expressed in ovarian tumors, 
secondary Müllerian structures and normal oviduct, but not OSE [28, 29].  Second, 
ovarian tumors are thought to arise in cystic structures that have no counterpart in 
normal ovary [25].  In addition, primary peritoneal carcinomas, which are 
histologically and clinically identical to ovarian carcinomas, arise outside of the ovary, 
even in individuals in whom the ovaries have been removed [25].  Finally, the tissues 
which ovarian epithelial tumors resemble, share a common embryological origin that 
is unrelated to that of the ovary [25]. 
These inconsistencies suggest that alternative sites of origin for epithelial 
ovarian tumors exist.  The secondary Müllerian structures have been proposed as one 
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alternative site [30].  Secondary Müllerian structures are normal structures outside of 
the uterus, cervix and fallopian tubes that are lined by Müllerian epithelium.  These 
structures include paraovarian/paratubal cysts and rete ovarii, as well as structures 
associated with endosalpingiosis and endometriosis (conditions in which uterine tube-
like epithelium is found outside of the uterine tube).  In particular, Dubeau proposed 
that the rete ovarii may be a site of origin on the basis that ovarian-like tumors arise 
from this structure in humans, and that ovarian epithelial tumors in rodents, although 
rare, frequently arise in rete ovarii as well [25, 30].  Experimental evidence for this 
hypothesis is limited and further studies are needed to confirm this source.  The 
fallopian tubes, another Müllerian site, have also been proposed as an alternative 
source of epithelial ovarian tumors.  The fimbriated end of the fallopian tube is in 
close contact with the ovarian surface, especially during ovulation, possibly resulting 
in the incorporation of preneoplastic or neoplastic cells from the fallopian tube into the 
ovary.  Evidence for this hypothesis comes from studies in women that are at high risk 
of ovarian cancer (BRCA+).  One study has shown that the fallopian tubes from these 
women have a high incidence of dysplasia [31].  Another study uncovered a high 
incidence of serous tubal intraepithelial carcinomas (TICs) in the fallopian tubes of 
BRCA+ women, but no carcinomas in ovaries [32].  Also, approximately one half of 
ovarian serous carcinomas were found to be associated with TICs of the fimbria [33].  
Furthermore, a putative precursor of serous carcinomas, termed the p53 signature, has 
been identified in the fimbria that shares characteristics with TICs [34].  Interestingly, 
p53 signatures are seen in the fallopian tubes of women that are BRCA+ and those 
with unknown BRCA status, but not inclusion cysts of the ovary [35], further 
supporting the idea that some epithelial ovarian cancers may arise in the fallopian 
tubes.               
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Ovarian tumors develop along two distinct pathways, possibly from different sites of 
origin 
Recently, researchers have proposed that epithelial ovarian tumors develop 
along two main pathways designated type I and type II [36]. Type I tumors develop in 
a step-wise manner from well characterized precursors (i.e. adenofibromas, 
cystadenomas and borderline tumors), and tend to be low grade, exhibit slow growth 
and remain confined to the ovary while growing to a large size [36, 37].  Low-grade 
serous, endometrioid, mucinous, and clear cell tumors all fit into this category.  
Interestingly, these tumors typically acquire mutations in genes belonging to signaling 
pathways controlling cell growth and proliferation, including KRAS, BRAF, PTEN, β-
catenin, and TGF-β RII [36].  Type I tumors are also associated with low cellular 
proliferation, a gradual increase in chromosomal instability and a 55% 5-year survival 
rate [36].  Type II tumors are thought to arise de novo (no identified precursors), and 
tend to be high grade and aggressive [36, 37].  This pathway includes high grade 
serous carcinoma and development of these tumors is associated with mutations in 
tumor suppressors that function in DNA damage signaling and repair including p53 
[38], or BRCA1, BRCA2, MLH1 and MLH2 [39]. Furthermore, these tumors exhibit 
high cellular proliferation, high chromosomal instability, and a 30% 5-year survival 
rate [36].  It should be noted that both pathways share common characteristics 
including escape from the immune response, the invasion into the stroma, survival and 
attachment within the peritoneal cavity, as well as growth and angiogenesis [40].  
Interestingly, Type I tumors constitute only 25% of ovarian tumors, while the vast 
majority (75%) of ovarian cancers are Type II [37].  This fact has a significant impact 
on clinical parameters such as early detection, diagnosis, and treatment [41]. 
A new model of ovarian cancer development has emerged that incorporates the 
alternative sites of origin discussed previously and Shih and Kurman’s two pathways 
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of tumor development [42] (Figure 1.1).  The first part of the model involves the OSE 
(Figure 1.1A).  In this scenario, OSE (or in some cases fallopian tube epithelium, 
endometrium, and peritoneum) can become trapped in inclusion cysts and induced to 
undergo Müllerian metaplasia within the ovarian stroma.  This process would give rise 
to endometrioid, mucinous, and serous borderline tumors in a step-wise progression 
[43] eventually resulting in the formation of type I tumors.  The second part of the 
model involves the fallopian tube fimbria (Figure 1.1B).  Accumulation of genotoxic 
stress and mutations in p53 could result in the formation of a preneoplastic lesion in 
which additional mutations could occur, leading to the formation of TIC.  TICs can 
spread to adjacent pelvic structures or exfoliate into the peritoneal cavity, resulting in 
the formation of type II tumors.  The lack of a precursor lesion in the ovary for type II 
tumors would be explained by this model.  Future studies are needed to validate this 
model, but it is clear that the origin and pathogenesis of ovarian cancer have 
implications for the clinical management of the disease [43, 44].                      
 
Steroid hormones and ovarian cancer 
Estrogen is associated with increased risk of ovarian cancer 
As discussed, steroid hormones, especially estrogen and progesterone, are thought to 
play a role in ovarian cancer.  Androgens have also been implicated in ovarian cancer 
progression, but the following discussion will focus on estrogen and progesterone.  
Numerous studies have shown that exogenous estrogen, in the form of hormone 
replacement therapy (HRT), is associated with an increased risk of ovarian cancer 
[13].  HRT is commonly prescribed to alleviate the symptoms experienced during 
menopause, and approximately 60 million prescriptions were written in the U.S. in 
2003 [45].  Current formulations of HRT are estrogen only or estrogen plus progestin, 
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Figure 1.1 Schematic diagram of a model of ovarian cancer development that incorporates 
alternative sites of origin [42]. 
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and it is believed that the risk of ovarian cancer is higher with estrogen only than with 
estrogen plus progestin [46-48].  This observation suggests that that addition of a 
progestin ameliorates the effect of estrogen and is consistent with the purported 
protective effect of progesterone in ovarian cancer.  Analyses have also shown that the 
duration of treatment may be important for ovarian cancer risk, with longer duration 
associated with increased risk that wanes after cessation of use [46, 47].   It should be 
noted, however, that some studies found HRT was associated with an increased risk of 
ovarian cancer regardless of the duration of use [49], as well as the formulation, 
estrogen dose, progestin type, regimen and route of administration [49, 50].   
Interestingly, studies have shown that the adverse effect of HRT use was 
stronger for endometrioid and clear cell tumors [18].  Endometrioid and clear cell 
tumor subtypes are associated with endometriosis, an estrogen-dependent condition, 
and it is thought that estrogen plays a role in the development of these subtypes [18].  
There are some beneficial effects of HRT, including protection against osteoporosis, 
heart disease and colorectal cancer [51], but the clear association with ovarian cancer 
should be taken into consideration regarding the use of HRT in women.  Obesity is 
another condition that is associated with increased ovarian cancer risk [13].  This may 
be due to an increase in unopposed estrogen through various mechanisms, including 
increased conversion of androgens to estrogen in adipose tissue, in obese women [52].  
Obesity also affects the clinical outcome of ovarian cancer with obesity associated 
with a higher mortality rate [53].  Conversely, lactation and oral contraceptive use, 
which are both associated with decreased estrogen levels, decrease the risk of ovarian 
cancer [54].  
Progesterone is associated with decreased risk of ovarian cancer 
As mentioned previously, pregnancy and oral contraceptive use are associated 
with a decreased risk of ovarian cancer [13], and this may be due to levels of 
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progesterone and action of progestins, respectively.  Circulating progesterone levels 
during pregnancy are increased 10-fold due to progesterone synthesis by the placenta 
[54].  Pregnancy is associated with a 40% decrease in risk of ovarian cancer and there 
is a 10-16% decrease in risk for each additional pregnancy [18].  Twin pregnancies are 
also associated with decreased risk of ovarian cancer, which is interesting because 
these women have higher gonadotropin levels and are more likely to double ovulate, 
factors that may put them at increased risk of the disease based on the incessant 
ovulation and gonadotropin hypotheses [54].  Twin pregnancies involve higher serum 
progesterone levels compared to single pregnancies [54], so this observed decreased 
risk suggests that progesterone is indeed protective.  It should be noted that pregnancy 
also raises serum estrogen levels about 100-fold [54], seemingly contradicting the 
aforementioned role of estrogen in ovarian cancer development.  After the first 4 to 5 
weeks of pregnancy, estrogens are mainly synthesized in the trophoblasts and the 
ovarian contribution is minimal, indicating that the OSE would not be exposed to high 
local levels of estrogen, and hence would accumulate less DNA damage [18].   
Oral contraceptives that contain progestin have also been shown to decrease 
the prevalence of ovarian cancer [13].  In fact, oral contraceptive use is associated 
with a 20% decrease in relative risk of ovarian cancer for every 5 years of use and 
longer duration of use further decreases the risk [55].  The effect is long-lasting with a 
reduction in risk for 30 years or more after use has ceased [55].  The effect of oral 
contraceptives on ovarian cancer prevalence has been attributed to the suppression of 
ovulation with these compounds (related to the incessant ovulation hypothesis); 
however, studies have shown that it may be the potency of the synthetic progestin 
itself that is responsible for the decrease in risk.  One line of evidence to support this 
hypothesis is that a decrease in ovarian cancer risk is seen in women who take 
progestin-only types of oral contraceptives comparable to that seen with combined OC 
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[54].  Up to 40% of women using the progestin-only methods continue to ovulate [16], 
suggesting that the risk reduction cannot be explained by the reduction of ovulatory 
events alone.  It should be noted that contraceptive progestins also exhibit variable 
androgenic properties and may lower androgen levels [54], providing another 
mechanism of action for the protective effect observed with respect to ovarian cancer.  
The use of oral contraceptives as chemopreventive agents will be discussed in the next 
section of the literature review.     
Steroid hormones exert their effects in target tissues through steroid receptors 
Effects of steroid hormones are mediated by interactions with their receptors in 
multiple target tissues throughout the body.  Steroid receptors are part of the nuclear 
receptor superfamily, which also include thyroid receptor, vitamin D receptor, retinoic 
acid receptor and others [56].  In general, steroid receptors are modular proteins 
composed of distinct regions, including a transactivation region (responsible for 
transcriptional activation), a DNA-binding domain, and a ligand-binding domain, 
which determine function and specificity [57].  Steroids bind to their respective 
receptors, resulting in binding of the ligand/receptor complex to response elements 
within the promoter of target genes.  Co-activators or co-repressors are then recruited 
to the promoter and gene transcription is either activated or repressed.  This represents 
the classical or genomic mechanism of signaling, but genomic signaling can also occur 
in the absence of ligand where phosphorylation of the receptor by kinases occurs in 
the absence of ligand binding and in a response-element-independent manner where 
the ligand/receptor complex binds to alternative binding sites in promoters of target 
genes.  Steroids can also signal through non-genomic mechanisms in which they bind 
to a receptor at the cell surface, triggering signal transduction pathways independent of 
gene transcription [58].  It is becoming increasingly clear that biological effects of 
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steroid hormone in target tissues are due to cross-talk between the genomic and non-
genomic signaling pathways [58].   
Thus far, two estrogen receptor subtypes, estrogen receptor 1 (ESR1) and 
estrogen receptor 2 (ESR2), have been identified.  These subtypes are encoded by 
different genes, have distinct biological functions and exhibit differential localization 
and expression patterns.  Knockout mice of the two subtypes exhibit different 
phenotypes, highlighting their distinct functions [59].  ESR1 and ESR2 exhibit 17%, 
97% and 60% sequence homology in the N-terminal domain (transactivation region), 
DNA-binding domain, and ligand-binding domain, respectively [59].  Similar to 
estrogen, progesterone also signals through its receptor resulting in downstream 
biological effects in the target tissue.  There are two isoforms of the progesterone 
receptor, PR-A and PR-B, which are the products of a single gene [60].  PR-A is a 
truncated form of PR-B, lacking amino acids 1-164 of the N-terminus of PR-B, due to 
differential splicing [60].  For the most part, PR-B acts as a transcriptional activator, 
while PR-A is transcriptionally inactive and acts a repressor of PR-B [60].  Selective 
ablation of PR-A and PR-B has confirmed that the tissue specific functions of the 
individual isoforms are distinct [60].   
Aberrant steroid hormone/receptor signaling may play a role in ovarian cancer 
Approximately 60% of human ovarian tumors express estrogen receptors [61, 
62] and they are most highly expressed in serous and endometrioid subtypes [63].  
Interestingly, ESR2 expression is significantly decreased in ovarian tumors compared 
to normal ovary [64, 65].  Decreased ESR2 is also evident in other cancers, including 
breast, colon and prostate, suggesting that loss of ESR2 may be a common step in 
estrogen dependent ovarian tumor progression [66].  On the other hand, ESR1 is the 
main form expressed in malignant ovarian tumors [65].  The ESR1/ESR2 ratio is also 
significantly increased in ovarian tumors [65] and ovarian cancer cell lines [67].  It is 
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thought that estrogen-driven growth in ovarian cancer cells is mediated by signaling 
through ESR1 [68], highlighting the importance of the increase in this ratio.  The 
significance of ESR2 expression is also supported by a recent study that reported an 
association of ESR2 expression with stage I disease, as well as longer disease-free and 
overall survival [69].  Approximately 49% of malignant ovarian tumors express 
progesterone receptors [70], with higher expression in the endometrioid subtype [71].  
Furthermore, one study showed that PR-B protein expression is up-regulated in 
malignant ovarian cancer cells versus normal ovarian epithelial cells [67].  Another 
study found a reduction in PR-A in ovarian cancer tissue compared to normal ovarian 
tissue, as well as an elevation of the PR-B/PR-A mRNA ratio in cancer cell lines 
treated with estrogen [53].  Further research is required to determine the significance 
of differential PR isoform expression in ovarian cancer tumorigenesis.   
There is some evidence that defects in the progesterone receptor itself may be 
related to increased ovarian cancer risk [54], but subsequent studies have failed to 
confirm this link [53].  Numerous studies have shown that progesterone receptor 
expression is a favorable prognostic indicator for ovarian cancer [72-74] and is 
associated with disease-free survival [75, 76], overall survival [76-78] early stage 
disease [77], low ascites volume [74], and higher tumor differentiation [74].  
Interestingly, one study found that low grade ovarian tumors expressed more estrogen 
and progesterone receptors, suggesting that these tumors may respond more readily to 
hormone therapy [79].    
Steroid hormones mediate cellular pathways that affect tumor development and 
progression 
Through interactions with their receptors, estrogen and progesterone affect 
multiple cellular pathways resulting in ovarian tumor development and progression.  
Ovarian tissue levels of estrogen are 100-fold higher than circulating levels [80] 
18 
suggesting that the OSE and its cystic derivatives are exposed to high levels of this 
steroid.  Studies in breast cancer have shown that estrogen, particularly its oxidative 
metabolites, can be genotoxic and directly damage DNA [81].  Estrogens stimulate 
proliferation in normal OSE [82], which could contribute to mutagenesis of these cells 
as well.  Estrogens have also been implicated in the progression of ovarian cancer by 
affecting cellular proliferation as well as invasion and metastasis [53, 71].  
Angiogenesis is an important process required for tumor growth, and estrogen 
metabolites have been implicated in this process as well [71].  One in vivo study 
reported that treatment of mice with estradiol resulted in an earlier onset of ovarian 
tumors and decreased overall survival time [83], further supporting the importance of 
estrogen in the development and progression of ovarian cancer.  As compared to 
estrogen, progesterone has been shown to inhibit ovarian cancer development and 
progression.  Several in vitro studies have shown that progesterone inhibits cell growth 
and induces apoptosis in OSE and ovarian cancer cells [53].  These effects are 
observed at higher concentrations of progesterone, similar to what is experienced 
during pregnancy.  One study in primates reported that levonorgesterol, a progestin, 
induced apoptosis in the OSE [84], which could be mediated by transforming growth 
factor β [85].  Progesterone has also been shown to induce differentiation-like 
characteristics in ovarian cancer cells and decrease ovarian cancer invasion by 
decreasing plasma membrane fluidity [71].  These studies support the hypothesis that 
progesterone is protective for ovarian cancer.                
Steroid hormone/receptor signaling can be targeted for therapy  
Clinical studies have been conducted to determine the efficacy of agents that 
target hormone signaling in ovarian tumors.  In general, hormonal therapy is well-
tolerated and relatively inexpensive, but has not been shown to be more effective than 
conventional chemotherapy as a first-line treatment [86].  Therefore, it is currently 
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used in women with refractory or recurrent disease that exhibits poor response to 
chemotherapy [86].  Selective estrogen receptor modulators (SERMs) and aromatase 
inhibitors have been tested to inhibit estrogen signaling.  SERMs, like estrogen, can 
bind to estrogen receptors and act either as agonists or antagonists in a tissue-
dependent manner.  Tamoxifen, one example of a SERM, has been shown to have 
antagonistic properties in breast tissue and behaves as an agonist in the uterus and is 
currently used as a therapeutic and chemopreventive agent for breast cancer [87].  In 
ovarian cancer, it is thought to exert an antiestrogen role by competitively binding to 
the estrogen receptor, blocking estrogen‟s effects on transcription [71].  Studies have 
shown a 13-17% response rate in women with ovarian cancer previously treated with 
tamoxifen [86].  There is some indication that patients with ER-positive tumors may 
have a higher response rate to tamoxifen, but further studies are needed to clarify this 
[71].  Chemotherapy is the first line of treatment for ovarian cancer and there is 
currently little evidence to indicate that the addition of tamoxifen enhances its effects 
[71].   
Aromatase inhibitors have also been tested as a therapeutic for ovarian cancer.  
Aromatase is the enzyme that is responsible for the conversion of androgens to 
estrogens, and contributes to the elevated circulating estrogens in post-menopausal and 
obese women [88].  Aromatase inhibitors act by inhibiting the production of estrogen, 
thereby decreasing the availability of estrogen for gene transcription, angiogenesis and 
DNA mutations [71].  Letrozole and anastrozole, aromatase inhibitors that are 
currently used to treat breast cancer, have been shown to have little to moderate 
activity in ovarian cancer [86].  Progesterone has been used to treat women with 
refractory or recurrent ovarian cancer with some success [71].  Although both 
estrogens and tamoxifen can induce progesterone receptor expression and may 
enhance treatment with progesterone, little to no response was seen with combination 
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hormonal therapy in recurrent or advanced ovarian cancer [71].  No response was 
observed in studies that utilized progestin in combination with chemotherapy, either 
[71].  One study tested the effects of a progestin as a front-line therapy in women with 
the endometrioid subtype of ovarian cancer [89].  The authors reported an overall 
response rate of 53.5%, with the highest incidence of tumor regression observed in 
tumors positive for both estrogen and progesterone receptors [89].  These results 
suggest that receptor status may be important in determining response to hormonal 
therapies.            
 
The use of oral contraceptives for chemoprevention of ovarian cancer  
Chemoprevention strategies for ovarian cancer are desirable 
Ovarian cancer has a high mortality rate and there are no accepted screening 
strategies which have been shown to decrease morbidity and mortality from the 
disease.  In fact, screening for ovarian cancer is not currently recommended for the 
general population, only for high risk individuals [90].  The high mortality of the 
disease and the difficulties with screening emphasize the need for prevention 
strategies.  Studies have shown that prophylactic oophorectomy can significantly 
reduce the risk of ovarian cancer in women with a family history of the disease [91].  
Women at high risk (BRCA+) are advised to undergo prophylactic oophorectomy at a 
young age (~35 years) and this procedure has some disadvantages in these patients, 
including the psychological impact of losing the ovaries, and early onset of 
menopausal symptoms [91].  Furthermore, women who undergo this procedure are 
still at risk for development of peritoneal carcinomas even in the absence of the 
ovaries [91].  It is clear that an alternative method of prevention, such as 
chemoprevention, is needed to protect women, especially those with a high risk, from 
developing ovarian cancer. 
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Possible chemopreventive agents for ovarian cancer include NSAIDs, retinoids and 
oral contraceptives  
Chemoprevention is the use of natural, synthetic, or biologic chemical 
compounds to prevent, inhibit or reverse the progression of cancer [92].  A diverse 
array of compounds have been shown to prevent the initiation  or progression of 
cancer, including vitamins, antioxidants, flavanoids, inhibitors of the cyclooxygenase 
pathway, steroid hormones, and retinoids [93].  These compounds can be divided into 
two major categories based on when they exert their preventive effects:  1) blocking 
agents, which inhibit tumor initiation by preventing carcinogens from reaching or 
reacting with target sites and 2) suppressing agents, which inhibit tumor progression 
[94].  Blocking agents can exert their effects by preventing carcinogen activation, 
enhancing detoxification of carcinogenic agents, or trapping cancer-producing 
compounds before they reach their targets [95].  Suppressing agents act by decreasing 
proliferation, increasing apoptosis and/or differentiation, and blocking oncogene 
activation [93, 95].   
 Studies have shown that non-steroidal anti-inflammatory drugs (NSAIDs), 
retinoids, and oral contraceptives may be putative chemopreventive agents of ovarian 
cancer.  NSAIDs, such as aspirin and ibuprofen, are drugs with analgesic, antipyretic, 
and anti-inflammatory effects.  Most NSAIDs work as non-selective inhibitors of the 
prostaglandin-endoperoxide synthases (PTSGs) which catalyze the formation of 
prostaglandins from arachidonic acid.  Prostaglandins can act as messengers in the 
inflammatory pathway, so blocking this conversion is beneficial for treating diseases 
associated with inflammation.  NSAIDs have been shown to decrease the risk of 
ovarian cancer [96-99], especially in nulliparous women and those who have never 
used oral contraceptives [100].  It is thought that NSAIDs can exert their protective 
effects by inhibiting proliferation, angiogenesis, and oxidative DNA damage in cancer 
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cells, as well as by increasing apoptosis [101].  Long-term use of NSAIDs may, 
however, result in adverse gastrointestinal effects, especially in individuals with 
previous history of gastrointestinal ulcers, bleeding disorders, and allergic reactions 
[102].  Further clinical trials are needed to assess the efficacy of NSAIDs as 
chemopreventive agents.   
Another group of putative chemopreventive agents, the retinoids, are natural 
and synthetic compounds that are related to vitamin A.  They have been shown to play 
roles in cell differentiation and proliferation [103].  Fenretinide (4-HPR), a synthetic 
retinoid, has been shown to inhibit the growth of ovarian cancer cells and induce 
changes typical of apoptosis [91].  One study showed that administration of 4-HPR 
induced apoptosis in monkey ovaries [104], further supporting the use of retinoids as 
chemopreventive agents.  In this study, 4-HPR was also tested in combination with 
oral contraceptives and this combination was shown to have a greater effect on 
markers associated with growth inhibition and apoptosis, than 4-HPR or oral 
contraceptives alone [104].  Side effects of retinoids are reversible and include skin 
dryness and irritation, although some retinoids have been identified as teratogens 
[105].  Prolonged use of 4-HPR, in particular, has minimal side effects, making it a 
good candidate as a form of chemoprevention [105]. 
 Oral contraceptives are associated with a decreased risk of ovarian cancer, 
even in women at high risk for the disease (BRCA+) [106], supporting their use as 
chemopreventive agents for the disease.  It has been estimated that greater than 50% of 
ovarian cancer cases in the United States can be prevented by the use of oral 
contraceptives for at least 4-5 years [91].  Oral contraceptives are commonly 
prescribed for the purpose of birth control and have been used by more than 300 
million women [107].  There are two widely available forms of oral contraceptives: 
combination estrogen and progestin and progestin only.  Combination oral 
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contraceptives are the most widely used oral contraceptives and contain low doses of 
estrogen (<35 ug) and progestin (0.1 to 1.5 mg) [108].  These types may or may not 
vary dosage throughout the regimen, but all are taken for 21 days followed by 7 days 
without medication [108].  They prevent pregnancy mainly by suppressing ovulation 
(estrogen) and through effects on cervical mucus and on the endometrium (progestin) 
[108].  The progestin-only oral contraceptive (the “mini-pill”) contains a small dose of 
progestin (<0.5 mg norethindrone or norgestrol) and must be taken every day 
continuously [108].  Women who take the progestin-only oral contraceptives may still 
ovulate, but pregnancy is prevented through progestin‟s effects on cervical mucus, and 
on the endometrium [108].   Another progestin-only contraceptive, the injectible 
contraceptive, is also a popular method of contraception world-wide.  Depo- 
medroxyprogesterone acetate (DMPA) is one such injectible contraceptive available in 
2 formulations: 150 mg/ml for intramuscular injection (IM) and 104 mg/0.65ml for 
subcutaneous injection (SC) [109].  Both are given at 3-month intervals and prevent 
pregnancy by inhibiting gonadotropin secretion thereby inhibiting follicle 
development and ovulation [109].  Combined oral contraceptives decrease the risk of 
ovarian cancer by 20% for each 5 years of use and the longer the duration of use, the 
greater the reduction in risk [55].  This reduction persists for more than 30 years after 
use has ceased, but becomes attenuated over time [55].  A protective effect of 
progestin-only oral [110] and injectible [54] contraceptives has also been observed, 
but further studies are needed to confirm this effect. 
The mechanism of oral contraceptive action is unclear  
Little is known about the mechanism of the protective effect of oral 
contraceptives.  It is thought that the protective effect might be related to the decrease 
in ovulatory cycles associated with oral contraceptive use.  This is consistent with the 
incessant ovulation hypothesis that states that the OSE are susceptible to genetic 
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mutations during ovulatory rupture and repair [15].  In women who have used oral 
contraceptives for at least 5 years, however, there is a 50% decrease in ovarian cancer 
associated with an estimated 15% decrease in ovulatory cycles [91].  In addition, 
women who use progestin-only oral contraceptives can ovulate, but still have a 
decreased risk as discussed previously.  These observations suggest that the protective 
effect of oral contraceptives may be due to a mechanism other than suppression of 
ovulation.  DMPA has been shown to inhibit the gonadotropin peak [111] and 
inhibition of gonadotropin release from the pituitary may also play a role in the 
protective effect.  This is consistent with the gonadotropin hypothesis that states that 
elevated gonadotropins play a role in the development and progression of ovarian 
cancer [17].  Finally, the hormonal components of oral contraceptives may induce 
apoptosis (progestin) and stimulate proliferation (estrogen) of susceptible OSE cells, 
consistent with the hormonal hypothesis [18].  The mitogenic role of estrogen has 
already been discussed in some detail with regard to hormone replacement therapy.  
There is some evidence for the protective effect of progestin from a study in monkeys 
[84].  In that study, progestin alone, and in combination with estrogen, increased 
apoptosis in the OSE, with maximal effect seen in the progestin alone group [84].  
Another study in a mouse model, however, showed no effect of progestin, alone or in 
combination with estrogen, on apoptosis, although a reduction of tumor weight was 
observed in both treatment groups [112].  The latter study was not directly testing the 
chemopreventive effect of progestin, since tumors were already present, but lack of 
apoptosis seen with progestin administration should be noted.  Further studies are 
needed to determine the mechanism of oral contraceptive action on ovarian cancer. 
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The side effects of oral contraceptive use, although minimal for most women, should 
be taken into consideration   
One problem with the use of oral contraceptives as chemopreventive agents is 
their association with negative side effects.  One major concern regarding the long-
term oral contraceptive use is the reported negative effect on cardiovascular health.  
Studies have shown that these effects are minimal in most patients; however, 
hypertension, smoking, obesity and diabetes may increase these risks [113].  Oral 
contraceptive use has also been associated with increased risk of breast and cervical 
cancers, but studies have shown that these increases are small [113].  There are some 
non-contraceptive health benefits of oral contraceptive use, including prevention of 
endometriosis and endometrial cancer, as well as treatment of menorrhagia, ovulatory 
pain, and acne [114].  In general, the benefits seem to outweigh the risks, but these 
side effects should be taken into consideration when considering the use of oral 
contraceptives for chemoprevention.            
 
Hen as a model for ovarian cancer 
Few animal models for ovarian cancer, aside from hens, develop the disease 
spontaneously at a high frequency  
Animal models of human ovarian cancer can shed light on the genetic and 
biological factors that influence tumor development and/or progression, as well as 
identify strategies for prevention, early detection and treatment.  Current animal 
models of ovarian cancer involve spontaneous or induced carcinomas and human 
xenografts [115].  Each model has its strengths and weaknesses, but a spontaneous 
model is desirable because it would most accurately recapitulate disease initiation and 
progression in women.  Most mammals, however, do not spontaneously develop 
ovarian carcinomas.  This is most likely due to the fact that most sexually mature 
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female mammals are either pregnant, lactating, or seasonally anestrous and hence have 
reduced numbers of ovulations.  Ovulation is associated with increased risk of ovarian 
cancer; therefore species that ovulate intermittently might have a decreased risk of the 
disease.  There have been reports of spontaneous ovarian cancer in rodents [116, 117] 
and non-human primates [118], but these cases are rare.    
In contrast, laying hens have a high spontaneous incidence of the disease that 
is age-dependent [119].  Numerous studies have characterized hen ovarian tumors and 
validated the hen as a model for human ovarian cancers.  Chicken ovarian tumors 
histologically resemble human ovarian tumors.  There are 4 subtypes of human 
ovarian adenocarcinomas including serous, endometrioid, mucinous and clear cell 
tumors and these subtypes are also observed in the hen [120-122].  Ovarian tumors of 
the hen express similar markers to tumors in women including progesterone receptor 
[123], prostaglandin synthases (PTGSs) [124, 125], CA-125 [126], vascular 
endothelial growth factor (VEGF) [127], cytochrome P450, family 1, subfamily B, 
polypeptide 1 (CYP1B) [128], HER2/neu [129], and E-cadherin [130].  In addition, 
hen ovarian tumors exhibit mutations in the tumor suppressor p53, which frequently 
occur in human ovarian tumors as well [129].  Production of antitumor antibodies is 
associated with tumors in human cancers and this is also observed in hens with 
ovarian cancer [122].  These studies have provided evidence that hen ovarian tumors 
are similar to tumors in women and support the usefulness of the hen as a model of 
ovarian cancer. 
Hens and humans exhibit several physiological differences limiting the use of the hen 
as a model for ovarian cancer 
There are limitations to using the hen as a model for human ovarian cancer.  
First of all, there is a difference in physiology between mammals and chickens.  In 
contrast to mammals, only the left ovary and oviduct develops in the hen.  During 
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development of the reproductive tract, anti-Müllerian hormone (AMH) acts to regress 
the right ovary and oviduct and it is thought that ovarian estrogen protects the left side 
of the reproductive tract from the effects of AMH [131].  In women with unilateral 
ovarian cancer, the contralateral ovary is examined for evidence of precursor lesions 
(i.e. abnormal OSE morphology, cortical invaginations, and inclusion cysts), shedding 
light on early events in ovarian cancer progression.  Involvement of the contralateral 
ovary (or lack thereof) is also used in staging ovarian cancer in women.  Since the hen 
lacks a second ovary, the information provided by examining the contralateral ovary is 
not readily accessible.  Hens and women also exhibit differences in reproductive 
cycles, including cycle length, steroid hormone responsible for the LH surge and 
formation of the corpus luteum.  The menstrual cycle in women lasts an average of 28 
days and the cycle in the hen is accelerated comparatively, lasting approximately 26 
hours.  In women, the LH surge is initiated by high levels of estradiol and occurs 
approximately 2 days before ovulation.  The LH surge in the chicken is triggered by 
progesterone approximately 4-6 hours before ovulation.  There is also no comparable 
luteal phase in chickens due to the lack of corpus luteum formation.  Instead, the 
postovulatory follicle is resorbed through apoptosis.  Finally, studies in the hen may 
be confounded by standard husbandry practices.  Ovarian cancer prevalence increases 
in older hens and one study showed that mortality rates increased after handling older 
birds for cage cleaning [132].  The aforementioned limitations, including the lack of a 
contralateral ovary, difference in reproductive cycle and fragility of older hens do not 
exclude the hen as a suitable animal model for ovarian cancer, but should be taken into 
consideration when designing and conducting experiments.         
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Studies in the hen have provided support for the “incessant ovulation” hypothesis, as 
well as a role for inflammation in ovarian cancer 
Despite the limitations discussed, studies in the hen have provided insight into 
the factors that may play a role in the development of ovarian cancer, including 
ovulation, inflammation and hormones.  As mentioned previously, most mammalian 
species do not spontaneously develop ovarian cancer and this may be related to the 
fact that these species do not ovulate with as much frequency as the human or hen.  
The hen ovulates approximately every 26 hours and it has been suggested that once a 
hen has reached her third year of egg-laying, she has ovulated approximately as many 
times as a peri-menopausal woman (~500 times) [130].  This observation of high 
ovulatory frequency in the hen and increased incidence of ovarian cancer supports the 
“incessant ovulation” hypothesis previously discussed.  In a previous study, our lab 
reported an association between the number of ovulatory events and the risk of ovarian 
cancer.  Giles et al discovered a decreased incidence of ovarian cancer in restricted 
ovulator (RO) hens compared to wild-type (WT) hens [133].  RO hens have a 
mutation that affects their ability to incorporate yolk into growing follicles and 
consequently ovulate fewer times than their WT counterparts [134].  It should be 
noted that although this association has been observed, studies have reported no 
significant difference in egg production in hens that develop ovarian cancer versus 
those that do not [119, 133], suggesting that other factors contribute to development of 
ovarian cancer in the hen. 
Related to the “incessant ovulation” hypothesis is the idea that inflammation is 
linked to ovarian cancer development.  Ovulation has been described as an 
inflammatory process [135] and it is thought that inflammatory factors produced 
during ovulation may induce DNA damage in the ovarian surface epithelium (OSE) at 
the site of ovulation [136].  Our lab has previously isolated and characterized chicken 
29 
OSE and shown that these cells express markers similar to human OSE [137].  
Another study has shown that DNA damage accumulates in OSE associated with pre- 
and postovulatory follicles in the laying hen [136], supporting the inflammation 
hypothesis.  Prostaglandins are thought to play a role in the inflammatory process and 
prostaglandin synthase 1 (PTGS1; one of the enzymes responsible for prostaglandin 
synthesis) is overexpressed in chicken ovarian tumors compared to normal ovaries 
[124, 125] and in the post-ovulatory follicle in normal hen ovaries [124].  
Interestingly, non-steroidal anti-inflammatory drugs (NSAIDs) that target 
prostaglandin synthase 1 have been shown to inhibit proliferation of chicken ascites 
cells in vitro [127] and inhibit progression of chicken ovarian cancer in vivo [139].  
Another study reported decreased severity of ovarian cancer in hens fed flaxseed, a 
source of omega-3 fatty acid which has been shown to reduce inflammation [140].  
These studies suggest that the inflammatory process associated with ovulation may 
play a role in the progression of ovarian cancer in the hen. 
More research is needed to elucidate the role of steroid hormones in ovarian cancer 
of the hen 
Few studies have directly examined the role of either gonadotropins or steroid 
hormones in hen ovarian cancer.  As mentioned previously, gonadotropins, estrogens 
and androgens are thought to promote ovarian tumor progression, while progesterone 
is protective.  Interestingly, the RO hens previously discussed have a hormone profile 
associated with increased risk of ovarian cancer including elevated levels of LH, FSH, 
and estrogen [133, 141] and decreased levels of progesterone [141].  These hens, 
however, have a decreased prevalence of ovarian cancer [133].  Fredrickson observed 
that plasma levels of steroid hormones were not associated with disease progression, 
except for elevated levels of plasma estrogen in hens with granulosa cell tumors [119].  
These studies would suggest that hormone levels may not be a contributing factor to 
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tumor progression in the hen; however, the effects of hormones were not measured 
directly in these studies.  One study directly tested the effect of progestin on ovarian 
cancer prevalence in the hen.  Hens treated with the progestin, medroxyprogesterone 
acetate (MPA), exhibited a decreased risk of ovarian cancer [142].  This effect could 
be due to the progestin itself, or the fact that progestin administration also resulted in a 
decline in egg production, thus further supporting the “incessant ovulation” 
hypothesis.  The information that we have regarding the role of hormones in ovarian 
cancer in the hen is thus far incomplete and further study is needed in this area.     
Studies in the hen can provide information about prevention, early detection, and 
development of ovarian cancer  
The hen has also proven to be a useful pre-clinical model to study prevention 
and early detection strategies.  Chicken ovarian tumors have been shown to express 
antigens that are useful surrogate biomarkers in chemoprevention trials, including 
proliferating cell nuclear antigen (PCNA), p27 and transforming growth factor-α 
(TGF-α) [143].  As mentioned previously, several studies have been conducted testing 
the preventative agents, progestin [142], aspirin [139], and flaxseed [140].  A 
significant reduction in either prevalence or stage was seen in all three studies 
demonstrating the merit of prevention studies in the hen.  The hen has also proven to 
be useful to study methods of early detection of ovarian cancer.  Studies have shown 
that the use of sonography aids in the accurate detection of ovarian tumors in the hen 
[120] and may help monitor early changes in the ovary associated with neoplastic 
progression, including tumor-associated neoangiogensis [144]. 
The hen animal model should also be used to identify early markers of the 
disease and to investigate the origin of ovarian cancer, since these areas of research 
will have a major impact on how women are diagnosed and treated.  Several 
immunohistochemical-based studies have been conducted to determine the origin of 
31 
ovarian cancer in the hen.  Haritani et al used an antibody against the oviductal protein 
ovalbumin to determine where tumors in the hen arise [145].  They found that all 
ovarian tumors examined expressed ovalbumin and concluded that most of the tumors 
in hens are of oviductal origin.  Our lab also determined ovalbumin expression in 
ovarian tumors, and divided the tumors into two groups: those with or without 
oviductal involvement [146].  Similar to Haritani et al, all ovarian tumors expressed 
ovalbumin, even in the absence of oviductal involvement.  It is clear that ovalbumin 
cannot be used to distinguish between ovarian tumors that originate in the ovary or the 
oviduct, but another marker that may be useful in this regard has been identified.  
Hakim et al reported that the majority of ovarian carcinomas, but few oviductal 
carcinomas exhibited significant HER2/neu expression [129].  HER2/neu expression 
may prove useful in distinguishing between these two sites of origin if it is shown that 
metastases from the oviduct to the ovary are also negative for HER2/neu.  Future 
studies regarding origin of ovarian cancer should take advantage of the hen model. 
Previous studies in the hen have characterized chicken ovarian tumors, yielded 
information about the development of ovarian cancer, as well as tested putative 
prevention and treatment strategies of the disease.  There are, however, major 
questions that remain unanswered.  For one thing, chicken ovarian tumors have yet to 
be fully characterized.  Most studies to date have focused on the expression and 
function of individual genes in chicken ovarian tumors, but no global gene expression 
profiling studies have been performed.  Gene expression profiling has yielded valuable 
prognostic and classification information for human ovarian tumors and can do the 
same for chicken ovarian tumors.  In order to further characterize chicken ovarian 
tumors, we performed microarray analysis to identify differentially expressed genes in 
chicken ovarian tumors versus normal ovary using microarray technology.  We also 
examined gene expression in early stage tumors, to obtain information about early 
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neoplastic events.  Second, it is known that steroid hormones play a role in ovarian 
cancer in women, but their roles in ovarian cancer of the hen has yet to be elucidated.  
In particular, oral contraceptive use is associated with a decreased risk of ovarian 
cancer.  We performed an in vivo study to determine the effects of the hormonal 
components of oral contraceptives, alone and in combination, on ovarian cancer 
prevalence in the hen and to investigate the mechanism of oral contraceptive action.  
Finally, estrogen/estrogen receptor signaling has been implicated in human ovarian 
cancer, but the estrogen receptor status of chicken ovarian tumors is unknown.  We 
determined the mRNA and protein expression of estrogen receptor subtypes in ovaries 
from hens with cancer versus in ovaries from normal hens.  We hypothesized that 
these studies would yield information about the development and progression of 
ovarian cancer in the hen, as well as in women.   
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CHAPTER 2 
 
GENE EXPRESSION PROFILING REVEALS DIFFERENTIALLY EXPRESSED 
GENES IN OVARIAN CANCER OF THE HEN: SUPPORT FOR OVIDUCTAL 
ORIGIN?  
 
Abstract 
Ovarian cancer has a high mortality rate due, in part, to the lack of early 
detection and incomplete understanding of the origin of the disease.  The hen is the 
only spontaneous model of ovarian cancer, and can therefore aid in the identification 
and testing of early detection strategies and therapeutics.  Our aim was to combine the 
use of the hen animal model and microarray technology to identify differentially 
expressed genes in ovarian tissue from normal hens compared to hens with ovarian 
cancer.  We found that the transcripts up-regulated in chicken ovarian tumors were 
enriched for oviduct-related genes.  Quantitative real-time PCR and 
immunohistochemistry confirmed expression of oviduct-related genes in normal 
oviduct and in ovaries from hens with early- and late-stage ovarian tumors, but not in 
normal ovarian surface epithelium (OSE).  In addition, one of the oviduct-related 
genes identified in our analysis, paired box 2 (PAX2) has been implicated in human 
ovarian cancer and may serve as a marker of the disease.  Furthermore, estrogen 
receptor 1 (ESR1) mRNA is over-expressed in early stage tumors, suggesting that 
expression of the oviduct-related genes may be regulated by estrogen.  We have also 
identified oviduct-related genes that encode secreted proteins that could represent 
putative serum biomarkers.  The expression of oviduct-related genes in early stage 
tumors is similar to what is seen in human ovarian cancer, with tumors resembling 
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normal Müllerian epithelium.  These data suggest that chicken ovarian tumors may 
arise from alternative sites, including the oviduct. 
 
Introduction 
Ovarian cancer is the fifth leading cause of cancer death in U.S. women and 
the leading cause of death from gynecologic cancer [1].  In 2009, the American 
Cancer Society estimated that greater than 14,000 women died from the disease.  The 
high mortality rate is due, in part, to limited early detection strategies and incomplete 
understanding of the origin of the disease.       
Gene expression profiling studies using DNA-microarray technology can 
advance the understanding of the etiology and progression of ovarian cancer.  The use 
of such technology has made it possible to analyze the expression of genes in small 
samples of tumor tissue on a global level.  Thus far, gene expression profiling has 
provided prognostic and classification information, as well as predictions of 
responsiveness to chemotherapeutics [2].  Further insights gained from these types of 
studies could eventually enhance the clinical management of the disease by providing 
potential markers for early diagnosis as well as novel therapeutic strategies. 
The hen is the only spontaneous animal model of ovarian cancer and can 
therefore aid in the identification and testing of early detection strategies and 
therapeutics.  Hens have a high incidence of ovarian cancer and similar to women, this 
incidence increases with age [3].  Several studies have reported that ovarian tumors of 
the hen express antigens that are frequently expressed in human ovarian tumors 
including cytokeratin, EGFR, HER-2/neu, COX-1, VEGF, and E-cadherin [4-9].  
Barua et al found that chicken tumors resemble all 4 phenotypes found in women, with 
serous and endometrioid tumors present at about equal frequencies [10].  A recent 
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study also showed that approximately half of ovarian tumors in the hen exhibit 
mutations in p53 similar to ovarian adenocarcinomas in women [9]. 
These studies and others have demonstrated the usefulness of the hen as a 
model to study the etiology and progression of ovarian cancer.  However, no studies to 
date have examined global gene expression in ovarian cancer of the hen.  To this end, 
we combined the use of the hen animal model with microarray technology to identify 
differentially expressed genes in ovarian tissue from normal hens compared to hens 
with ovarian cancer.  One advantage of this approach is that differentially expressed 
genes identified can be evaluated in early stage tumors, providing information about 
changes that occur during early neoplastic events.  We also evaluated expression of 
particular genes at different stages to assess changes associated with tumor 
progression.   
 
Materials and Methods 
Animals and tissue collection 
Single-comb White Leghorn hens were individually caged with access to food 
and water ad libitum.  Hens were maintained on a 15h light and 9h dark schedule.  All 
animal procedures were approved by the Institutional Animal Care and Use 
Committee of Cornell University. 
Normal ovarian tissue samples and ovarian tumor tissue samples from 2.5 to 
4.5 year old hens were collected and either frozen in liquid nitrogen or placed in 
RNAlater [11].  Additional samples were placed in cassettes in formalin for paraffin 
embedding for immunohistochemical analysis.  Diagnosis of hens was made by gross 
observation and confirmed by analysis of hematoxylin and eosin stained paraffin 
embedded sections.  Ovarian tumors were staged as previously described [11] (Table 
2.1). 
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Microarray analysis 
Hens used for microarray analysis were between 2.5 and 3.5 years of age.  
Normal hens (n=3) showed no gross or histopathological evidence of ovarian cancer, 
while cancer specimens (n=3) were stage 2 or 3 (Table 2.1).  Total RNA was extracted 
 
              Table 2.1  Stages of ovarian cancer in the hen [11]. 
 
Stage Description 
1 Tumor restricted to ovary and only detectable by histology 
2 Tumor restricted to ovary and observable at necropsy 
3 Ovarian tumor with abdominal seeding 
4 Ovarian tumor with abdominal seeding and ascites 
 
from the frozen normal ovarian tissue and ovarian tumor tissue using TRIZOL 
(Invitrogen, Carlsbad, CA) and RNA integrity was verified using the 2100 Expert 
Bioanalyzer (Agilent Technologies, Santa Clara, CA).  Linear amplification and 
labeling was carried out to produce an antisense RNA (aRNA) target.  The labeled 
aRNA was hybridized to GeneChip® chicken genome arrays (Affymetrix, Santa 
Clara, CA) and scanned by the GeneChip scanner 3000-7G.  Analysis of the raw data 
(including the .CEL files) was carried out at the DNA microarray core facility (Cornell 
University, Ithaca, NY) using the Affymetrix GCOS software.  A set of 273 
differentially expressed genes was selected based on a t-test P value less than 0.01 and 
fold change greater than 1.5.  These data are included as Appendix 1 and have been 
deposited in the Gene Expression Omnibus (GEO) public repository (accession 
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number GSE21706).  Functional annotation analysis was subsequently carried out 
using DAVID Bioinformatics Resources 2008 [12, 13]. 
Real-time quantitative PCR 
Total RNA was extracted from normal hen ovarian tissue (n=8), ovarian tissue 
from hens with stage 1 (n=3), stage 2 (n=2), stage 3 (n=6) and stage 4 (n=7) tumors 
using the RNeasy Mini kit (Qiagen, Valencia, CA).  Extracted RNA was reverse-
transcribed into cDNA and the cDNA was used for quantitative PCR with SYBR 
Green to determine mRNA expression levels of several genes selected for further 
study based on the functional annotation analysis of microarray data (DAVID).  These 
were the oviduct-related genes: Serpinb14, more commonly known as ovalbumin 
(Oval), paired box 2 (Pax2), ovomucoid (Ovm), Serpinb14b, more commonly known 
as serpin peptidase inhibitor clade B member 3 (Serpinb3), transferrrin, also known as 
lactotransferrin (Ltf), and LOC396449 which encodes riboflavin binding protein (RD).  
Chicken specific primers (designed to span introns) were designed using 
OligoPerfect
TM
 Designer (Invitrogen, Carlsbad, CA) or Primer Express software v2.0 
(Applied Biosystems, Foster City, CA).  The oligonucleotide sequences of primers are 
listed in Table 2. Control reagent was Quantum RNA Universal 18S primers (Ambion, 
Austin, TX).  Control reactions containing no template and reactions lacking reverse 
transcriptase were also run.  Total volume of reactions was 25 uL with a final 
concentration of 1X Power SYBR Green PCR Master Mix (Applied Biosystems, 
Foster City, CA), 0.3 nM of primer pairs for the oviduct-related genes, and 0.1 nM of 
primer pairs for 18S.  All sample reactions were run in duplicate using the ABI Prism 
7000 Sequence Detection System.  The relative amount of mRNA in a particular 
sample was determined by the comparative threshold cycle (Ct) method using 
Sequence Detection System software (Applied Biosystems, Foster City, CA).           
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Laser capture microdissection  
Hens with early stage (stage 1, as defined in Table 2.1) ovarian cancer were 
identified by analyzing paraffin embedded sections that were stained with hematoxylin 
and eosin.  Ovarian samples from these hens had also been embedded in Histo Prep 
(Fisher Scientific, Pittsburgh, PA) and snap frozen in cryomolds.  Frozen sections of 
ovary from these hens (n=5) as well as sections of ovary and oviduct from normal 
hens (n=5) were cut, placed on PEN-membrane slides (Leica Microsystems, Wetzler, 
Germany), stained briefly with hematoxylin, and processed in a solution of 70% 
ethanol.  Slides were allowed to dry before laser capture of tissue.  Normal oviduct, 
ovarian epithelial cells (OSE), tumor and adjacent stromal tissue were captured using a 
laser capture microdissecting scope (Leica ASLMD, Leica Microsystems, Wetzler, 
Germany).  Total RNA was extracted using the RNeasy Plus Micro kit (Qiagen, 
Valencia, CA) and was reverse transcribed into cDNA.  As described previously, the 
cDNA was used for quantitative PCR with SYBR Green to determine mRNA 
expression levels of the oviduct-related genes Oval, Pax2, Ovm, Serpinb3, Ltf, and Rd.   
Expression levels of estrogen receptor 1 (estrogen receptor alpha; Esr1) and 
estrogen receptor 2 (estrogen receptor beta; Esr2) were also determined in these 
samples.  Briefly, chicken specific TaqMan primers and probes were designed using 
Primer Express software v2.0 (Applied Biosystems, Foster City, CA).  The sequences 
of primers and probes can be seen in Table 2.2.  TaqMan primers and probes for 18S 
(Applied Biosystems, Foster City, CA) were used as control.  Total volume of 
reactions was 25 uL with a final concentration of 1X TaqMan Universal PCR Master 
Mix (Applied Biosystems, Foster City, CA), 900 nM of estrogen receptor primer pairs 
(Esr1 and Esr2), 50 nM of 18S primer pair, and each respective TaqMan probe (250 
nM of estrogen receptor probes (Esr1 and Esr2) and 200 nM of 18S probe).  All 
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sample reactions were run in duplicate and the relative amount of RNA in a particular 
sample was determined as described above. 
 
Table 2.2 Primers used for real-time quantitative PCR analysis. 
 
Gene Gene accession 
no. 
Forward primer Reverse primer Probe 
OVAL NM_205152 cacaagcaatgcctttcaga gacttcatcaggcaacagca N/A 
OVM NM_001112662 tcgtgctgttctctttcgtg taggcacacagcaagcaatc N/A 
SERPINB3 NM_001031001 ggggcaagaggtaacactga gtagcatttggcctggtgat N/A 
LTF NM_205304 ctacagtgccatccagagca tgatgcagtcctttgtctg N/A 
RD NM_205463 gcctgcaaagatgattccat gccaccatgtccttccttgtt N/A 
PAX2 NM_204793 cgagtttttgagcgtccttc aaggtggtgcttgccatatc N/A 
ESR1 NM_205183 cagcattcgtgagaggatgtcta acagtaccgggtctccttggt taccaatgagaaagggagcctgtccatg 
ESR2 NM_204794 ggaaatgctatgaagtgggaatg acagtaccgggtctccttggt tgggtatcgaatcctgcgcc 
 
Immunohistochemistry 
Previously collected ovarian samples (n=6 normal; n=14 tumors of various 
stages) had been fixed in formalin, embedded in paraffin and cut at 4μm.  Paraffin 
sections were deparaffinized and rehydrated through a series of treatments with xylene 
and ethanol.  Sections were boiled in citrate buffer for antigen retrieval and blocked in 
10% goat serum in PBS for 30 minutes.  Sections were then incubated with mouse 
anti-chicken ovalbumin (Sigma-Aldrich, St. Louis, MO) at a dilution of 1:500 and 
rabbit anti-human PAX2 (Abcam, Cambridge, MA) at a dilution of 1:50 overnight at 
4°.  Control slides were incubated without primary antibody.  This was followed by 
incubation in AlexaFluor 594 goat anti-mouse IgG secondary antibody (0.24 ug/ml) 
for ovalbumin and AlexaFluor 488 goat anti-rabbit IgG (0.24 ug/ml) for PAX2 for 1h 
at 39°.  Normal ovarian samples (n=6) and ovarian samples from hens with stage 1 
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(n=3), stage 2 (n=2), stage 3 (n=4) and stage 4 (n=5) cancer were incubated with both 
primary antisera.  Slides were viewed using a Nikon eclipse E600 and pictures were 
taken with a Spot RT Slider camera. 
Statistics 
Relative expression values from real-time quantitative PCR analysis were log 
transformed and analyzed for significance using proc GLM.  Means were compared 
using Duncan’s multiple range tests.  Relative expression of estrogen receptor in 
microdissected tumor tissue compared to the adjacent stroma was analyzed using proc 
TTEST.  All tests were carried out using SAS version 9.2 with a significance level of 
p<0.05.  
 
Results 
Up-regulated transcripts in ovarian tumors are enriched for oviduct-related genes  
Out of >32,000 transcripts represented on the chicken GeneChip, 273 were 
differentially expressed between normal ovarian tissue and ovarian tissue from hens 
with cancer.  Of these, 153 transcripts were up-regulated and 120 were down-
regulated in tumor tissue.  A full list of these genes is provided in Appendix 1 and can 
be accessed through GEO (accession number GSE21706).  Figure 1 is a heat map of 
the top 25 up-regulated and down-regulated genes.  Functional annotation analysis 
(DAVID) revealed that the up-regulated transcripts are enriched for genes that are 
normally expressed in the oviduct.  Several of these genes are associated with the 
annotation keywords allergen and egg white, including Oval, Ovm, Ltf, Rd, and 
Serpinb3.  A literature search revealed several more oviduct-related genes identified in 
our microarray analysis (including meleagrin, lysozyme, gallicin 11 and beta-defensin 
12) and also confirmed that these genes encode proteins that are either expressed in 
the chicken oviduct [14], or secreted by oviductal cells to form membranes of the 
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developing egg [15, 16].  Pax2 is expressed in the female reproductive tract, including 
the oviduct, and is required for Müllerian duct development [17].  In total, 10 out of 
the top 25 up-regulated genes (40%) are oviduct-related.  These oviduct-related genes 
are consistently up-regulated in all three ovarian tumors as compared to normal ovary 
(Figure 2.2). 
 
Real-time quantitative PCR confirms increased expression of a subset of oviduct-
related genes in ovarian cancer of the hen 
Quantitative PCR was performed for a subset (selection was made based on 
our ability to design intron-spanning primers) of the 10 oviduct-related genes: Oval, 
Pax2, Ovm, Serpinb3, Ltf, and Rd.  All of these genes exhibited significantly higher 
(p<0.01) expression in tumor tissue (particularly later stages) as compared to normal 
tissue validating the microarray results (Figure 2.3).  Moreover, there was a stage-
dependent increase in expression of these genes in the tumors.  In all cases, expression 
was significantly greater in advanced tumors (stages 3 and 4) as compared to the 
earliest tumors (stage 1) or normal ovary (Figure 2.3).  Furthermore, several of the 
genes exhibited significantly higher expression in stage 2 tumors compared to normal 
ovary, including Oval, Pax2, Ovm, and Ltf (Figure 2.3).  The limited expression of 
these genes in stage 1 tumors could be due to the fact that samples from these tumors 
are composed primarily of normal tissue with only scattered areas of neoplasia.   
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Figure 2.1 Gene profile of 50 differentially expressed genes in chicken ovarian 
tumors.  The top 25 up- and down-regulated genes are depicted.  Genes were 
identified by Affymetrix ID (Gene ID), gene symbol and gene name.  Each column 
represents a single sample.  The shades of red indicate induced genes and the shades 
of green indicate the repressed genes.  Colored pixels indicate the magnitude of gene 
response. 
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Figure 2.2 Graphical representation of microarray results for the 10 oviduct-related 
genes in the top 25 up-regulated genes in ovarian tissue from three individual normal 
hens (1-3) compared to tissue from three individual hens with cancer (4-6). 
 
 
 
 
 
 
 
60 
 
Figure 2.3 Real-time quantitative PCR analysis of OVAL (A), PAX2 (B), OVM (C), 
SERPINB3 (D), LTF (E), and RD (F) mRNA expression in normal ovary (n=8), as 
well as stage 1 (n=3), stage 2 (n=2), stage 3 (n=6) and stage 4 (n=7) ovarian cancer.  
Means were compared using Duncan‟s multiple range tests.  Different letters indicate 
significant differences (p<0.01).  Means that share a letter are not significantly 
different.  Bars indicate standard error.   
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Expression of oviduct-related genes in early stage ovarian cancer compared to normal 
oviduct and OSE 
In order to investigate expression of these genes in early stage ovarian tumors, 
as well as in oviduct and OSE, we performed laser capture microdissection.  Oviduct 
and OSE from normal hens, as well as from neoplastic areas and adjacent stromal 
tissue from stage 1 ovarian cancers were microdissected from frozen ovarian sections.  
Figure 2.4 shows representative images of the microdissected oviduct, OSE, cancer 
and stromal tissue.  Quantitative real-time PCR was performed for the oviduct-related 
genes: Oval, Pax2, Ovm, Serpin3, Ltf, and Rd as above.  These oviduct-related genes 
are generally expressed in normal oviduct and early stage ovarian tumors, but not 
normal OSE (Figure 2.5).  Specifically, expression of Pax2 (p<0.001; Figure 2.5B), 
Serpinb3 (p<0.05; Figure 2.5D), Ltf (p<0.01; Figure 2.5E) and Rd (p<0.05; Figure 
2.5F) mRNA are significantly greater in early tumors compared to adjacent stroma 
and/or normal OSE.  There is also a trend for higher Oval and Ovm mRNA expression 
in early stage tumors compared to the surrounding stroma and normal OSE (Figure 
2.5A, 2.5C).  
 
Expression of estrogen receptors in early stage ovarian cancer 
We also determined expression of Esr1 and Esr2 in the microdissected 
neoplastic areas and adjacent stromal tissue.  Relative expression of Esr1 mRNA was 
significantly higher in microdissected tumor tissue compared to adjacent stroma 
(p<0.05; Figure 2.6).  Esr2 mRNA was not detectable in microdissected tumor or the 
adjacent stroma (data not shown).   
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Figure 2.4 Representative images of oviduct (A-C), OSE (D-F), as well as tumor and 
adjacent stromal tissue (G-I) before and after microdissection.  A) Frozen section of 
normal oviduct with tubular glands (arrow; 20X).  B) Image of oviduct section before 
microdissection.  Dashed line indicates area of tubular glands to be captured (10X).  
C) Image of oviduct section after microdissection (10X).  D) Frozen section of normal 
ovary with OSE (arrow; 20X).  E) Image of ovary section before microdissection.  
Dashed line indicates area of OSE to be captured (10X).  F) Image of ovary section 
after microdissection (10X).  G) Frozen section of ovary from hen with early stage 
cancer.  Tumor exhibits gland-like structures (arrow; 20X).  H) Image of ovary section 
before microdissection.  Dashed line indicates area of neoplastic cells to be captured 
while dotted line indicates area of apparently normal adjacent stroma to be captured 
(10X).  I) Image of ovary section after microdissection (10X).     
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Figure 2.5 Real-time PCR analysis of OVAL (A), PAX2 (B), OVM (C), SERPINB3 
(D), LTF (E), and RD (F) mRNA expression in microdissected oviduct (n=5), OSE 
(n=5), tumor (n=5) and adjacent stroma (n=5).  Means were compared using Duncan‟s 
multiple range tests.  Different letters indicate significant differences (p<0.05).  Means 
that share a letter are not significantly different.  Bars indicate standard error. 
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Figure 2.6 Real-time PCR analysis of ESR1 mRNA expression in microdissected 
tumor (n=5) and adjacent stroma (n=5).  Asterisk indicates significant difference 
(p<0.05).  Bars indicate standard error. 
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Chicken ovarian tumors express PAX2 protein 
Figure 2.7 illustrates that ovalbumin and PAX2 protein were expressed in early 
(stage 1) and late stage (stage 3) ovarian cancers of the hen.  Ovalbumin and PAX2 
protein expression were assessed in normal ovarian structures, including OSE, in 
normal ovaries and ovaries from hens with cancer.  In addition, expression of 
ovalbumin and PAX2 was also determined in neoplastic areas in ovaries from hens 
with cancer.   
As expected, no ovalbumin expression was detected in normal ovary (Figure 
2.7A), but ovalbumin was expressed in an early-stage tumor while the surrounding 
stroma was negative (stage 1; Figure 2.7C).  As previously reported, ovalbumin 
expression was seen in a late-stage ovarian tumor (stage 3; Figure 2.7E).  There was 
little to no expression of PAX2 in the normal ovary (Figure 2.7B).  There was nuclear 
PAX2 expression localized to neoplastic cells in an early stage tumor (Figure 2.7D, 
arrow) and nuclear expression in a late stage tumor (Figure 2.7F).  Control sections 
incubated without primary antibody were negative (insets Figures 2.7A-F).  Table 2.3 
summarizes the results obtained for all of the ovarian tissue sections examined.  All of 
the ovarian cancers expressed ovalbumin regardless of stage.  Similar to ovalbumin, 
PAX2 was expressed in ovarian tumors of all stages, but fewer stage 4 tumors were 
positive. 
 
Discussion 
To our knowledge, we are the first to report analysis of gene expression of 
ovarian cancer in the hen on a global level.  Through the current approach, we have 
identified genes that are differentially expressed in ovarian tissue from normal hens 
compared to tissue from hens with ovarian cancer.  Furthermore, functional annotation 
analysis revealed that 10 of the top 25 up-regulated genes (40%) in chicken ovarian  
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Figure 2.7 Immunohistochemistry with antibodies against ovalbumin and PAX2.  
Ovalbumin protein expression in normal ovary (A), early-stage ovarian cancer (stage 
1; C), and late-stage ovarian cancer (stage 3; E).  PAX2 protein expression in normal 
ovary (B), early-stage ovarian cancer (stage 1; D; arrow indicates area of neoplastic 
cells), and late-stage ovarian cancer (stage 3; F).  Control sections were incubated 
without primary antibody (insets A-F).  Scale bar = 100 um.     
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Table 2.3 Summary of ovalbumin and PAX2 protein expression in normal ovarian 
tissue (n=6), and ovarian tissue from hens with stage 1 (n=3), stage 2 (n=2), stage 3 
(n=4), and stage 4 (n=5) ovarian cancer. 
 
Type Ovalbumin+ (%) PAX2+ (%) 
Normal 0/6 (0) 0/6 (0) 
Stage 1 3/3 (100) 2/3 (67) 
Stage 2 2/2 (100) 2/2 (100) 
Stage 3 4/4 (100) 3/4 (75) 
Stage 4 5/5 (100) 1/5 (20) 
 
tumors are oviduct-related.  We have shown that these genes are expressed in early 
and late stage chicken ovarian tumors, as well as in the oviduct, but not OSE (Figures 
2.3 and 2.5), suggesting that ovarian tumors of the hen may originate from sites other 
than the OSE.  Alternatively, expression of oviduct-related genes in chicken, as well 
as human, ovarian tumors might suggest secondary Müllerian origin of these tumors 
[reviewed in 18 and 19], or aberrant differentiation of OSE [reviewed in 20], as has 
been proposed in women.  Despite the fact that ovarian cancer is a heterogeneous 
disease comprised of a variety of subtypes, the OSE has traditionally been viewed as 
the common origin of ovarian tumors.  However, recent studies have suggested that a 
subset of ovarian tumors might arise from sites other than the OSE, including the 
fallopian tubes [21].  For one thing, BRCA+ women who have a high risk of ovarian 
cancer also have a high incidence of epithelial dysplasia [22] and serous tubal 
intraepithelial carcinomas [23] in the fallopian tubes.  In addition women with serous 
ovarian carcinomas (regardless of BRCA status) exhibit involvement of the fallopian 
tubes as well as tubal intraepithelial carcinomas [24].  These results suggest that high 
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grade serous ovarian tumors may be of tubal origin.  These tumors are characterized 
by p53 mutations and over-expression of the HER2/neu oncogene [25].  Interestingly, 
ovarian adenocarcinomas in the hen also exhibit mutations in p53 and over-expression 
of HER2/neu [9], and therefore resemble high grade human ovarian cancers.   
Further evidence of a possible alternative site of origin of ovarian tumors 
comes from expression studies of paired box 2 (PAX2) in human ovarian tumors.  
Studies have shown that PAX2 mRNA and protein are expressed in the human 
reproductive tract and ovarian tumors [26, 27].  These studies also reported that OSE 
does not express PAX2 [26, 27], however, one study did find expression of PAX2 in 
normal OSE [28].  PAX2 expression has been reported in both low grade and high 
grade ovarian tumors [26], although Tung et al. found that few high grade ovarian 
tumors express PAX2 [27].  Although we did not evaluate PAX2 expression based on 
tumor grade, we did evaluate PAX2 expression in chicken ovarian tumors of all stages 
and found that fewer late stage tumors express PAX2 protein (Table 2.3).  This result 
is in contrast to the PAX2 mRNA expression data (Figure 2.3), suggesting that 
translation of PAX2 protein is altered in late stage tumors and that PAX2 may play a 
role in early tumor development.  Additionally, we have shown that PAX2 mRNA and 
protein are expressed in chicken ovarian tumors, but no Pax2 mRNA was detected in 
OSE (Figure 2.5), although a few scattered positive cells were observed in the OSE by 
immunohistochemistry (Figure 2.7).  These results are generally supportive of an 
oviductal site of origin, but could indicate a role for de-differentiation of the OSE.  We 
have also observed PAX2 mRNA and protein (Figure 2.5 and Appendix 2) expression 
in chicken oviduct, confirming that it is an oviduct-related protein.  It is possible that 
PAX2 may be playing a role in the progression of ovarian cancer in the hen, since it 
has been shown to be required for human ovarian cancer cell survival [29].  Future 
studies are needed to elucidate the role of PAX2 in ovarian cancer of the hen.  It 
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should be noted that another PAX family member, PAX8, is similar to PAX2 in amino 
acid sequence and has also been implicated in the development of ovarian cancer [30].  
PAX8 has yet to be identified in chicken, so it is not known how similar these 
sequences would be in the hen.  We performed a BLAST search with the peptide 
sequence of the immunogen of our antibody and identified PAX2, but not PAX8, in 
the human.  The BLAST search also identified PAX2 in other species, including the 
chicken.  Therefore, assuming that chicken PAX8 exists and has a similar sequence to 
chicken PAX2 (as seen in humans), it is likely that our antibody is specific for PAX2. 
Interestingly, a number of oviduct-related genes identified in our analysis are 
estrogen-regulated.  It has long been known that estrogen is responsible for the 
differentiation of oviductal glands that synthesize the major egg-white proteins in the 
chicken oviduct [reviewed in 31].  Estrogen has been shown to have a direct effect on 
the synthesis of ovalbumin, lactotransferrin, ovomucoid and lysozyme in the chicken 
oviduct [32].  In humans, PAX2 expression has also been shown to be activated by 
estrogen in endometrial cancer cells [33, 34].  Estrogen is thought to promote ovarian 
tumor progression by regulating cellular proliferation, motility and invasion and these 
effects are thought to be mediated by ESR1 [35].  We have shown that Esr1 mRNA 
expression is significantly higher in microdissected tumor tissue as compared to 
adjacent stroma (Figure 2.6), suggesting that expression of the oviduct-related genes in 
these tumors may be regulated by estrogen. 
As mentioned previously, some of the oviduct-related genes identified in our 
analysis encode proteins that are secreted by oviductal cells to form the membranes of 
the developing egg [15, 16].   The identification of up-regulated genes that encode 
secreted proteins in ovarian cancer provides the possibility of utilizing serum levels of 
these proteins as biomarkers for the malignancy.  Several current and potential serum 
biomarkers of ovarian cancer in humans have been shown to be normally expressed in 
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the oviduct including CA-125 [36], human epididymis protein 4 (HE4) [37] and 
oviductal glycoprotein 1 (OVGP1) [38, 39].  A number of the oviduct-related genes 
identified in chicken ovarian tumors encode proteins that are secreted and may 
represent serum biomarker candidates.  In particular, the genes encoding PAX2, 
SERPINB3, LTF and RD are expressed in early stage chicken ovarian tumors (Figure 
2.5), suggesting these proteins may serve as putative early markers of the disease.     
Our results support previous studies in the hen which reported increased 
expression of ovalbumin and E-cadherin in chicken ovarian tumors [40, 8].  
Ovalbumin and E-cadherin are in the list of the top 25 up-regulated genes in ovarian 
tumor tissue compared to normal ovarian tissue with expression levels increased 
>200-fold and 40-fold, respectively (Appendix 1).  Our results also support previous 
studies in women which reported over-expression of E-cadherin [41] and claudin 3 
[42] in human ovarian tumors.  As mentioned previously, E-cadherin has been shown 
to be up-regulated in chicken ovarian tumors compared to normal ovarian tissue.  
Claudin 3 is also over-expressed in chicken ovarian tumors.  Our microarray analysis 
revealed that it is in the top 25 up-regulated genes in chicken ovarian tumor tissue 
compared to normal ovarian tissue with expression levels increased >40-fold 
(Appendix 1).  In the current study, we focused on the genes up-regulated in ovarian 
tumors of the hen and have yet to study the down-regulated genes in depth.  It is 
possible, however, that putative tumor suppressors have been uncovered in our results 
and further studies are warranted. 
 Studies in women have identified common genetic alterations in ovarian 
cancer, including alterations of oncogenes such as HER2/neu, K-ras, PIK3CA, and c-
myc, as well as of tumor suppressors including p53 and BRCA1/2 [41].  Some of 
these alterations include overexpression (i.e. HER2/neu) and, surprisingly, we did not 
identify these genes in our microarray analysis.  In order to further investigate the 
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function of the genes identified, we performed a preliminary pathway analysis using 
the Ingenuity Pathway Analysis (IPA) program.  The top 5 network pathways 
identified by IPA are provided in Appendices 3A-E.  Interestingly, the oncogenes 
PI3K (Appendix 3B) and myc (Appendix 3C) and the tumor suppressor p53 
(Appendix 3E) are represented in the pathways created.  These data suggest that 
although these genes were not identified in our microarray analysis, they may possibly 
play a role in ovarian tumorigenesis in the hen.  Furthermore, we have also identified 
VEGF signaling in this analysis (Appendix 3A) which supports a previous study in the 
hen [7].  Our pathway analysis also supports our current data which suggest a role for 
estrogen/ estrogen receptor signaling, with beta estradiol signaling represented in 
Appendix 3E.  Further analysis is needed to fully comprehend the complex signaling 
pathways involved in ovarian tumor development and/or progression in the hen.   
Our analysis has revealed up-regulation of oviduct-related genes in chicken 
ovarian tumors, particularly at early stages, compared to normal ovarian tissue.  These 
results provide evidence that chicken ovarian tumors resemble normal Müllerian 
epithelium, similar to tumors in women and suggest a possible alternative site of 
origin of these tumors.  Although we have not disproven the possibility of secondary 
Müllerian structures or the OSE as sites of origin, we hope that our data can stimulate 
additional work in this area.  We have also shown that the oviduct-related genes may 
also be regulated by estrogen, highlighting the importance of estrogen signaling in 
these tumors.  In addition, a number of these genes are secreted and may prove to be 
possible serum biomarkers.  Importantly, our studies further validate the use of the hen 
as a model for human ovarian cancer. 
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CHAPTER 3 
 
ORAL CONTRACEPTIVES DECREASE THE PREVALENCE OF OVARIAN 
CANCER IN THE HEN 
Abstract 
Ovarian cancer is the leading cause of reproductive cancer death in U.S. 
women.  This high mortality rate is due to the lack of early detection methods and 
ineffectiveness of therapy for advanced disease.  Until more effective screening 
methods and therapies are developed, chemoprevention strategies are warranted.  The 
hen has a high spontaneous prevalence of ovarian cancer and is suitable for studying 
ovarian cancer chemoprevention.  Our objective was to determine the effect of 
progestin alone, estrogen alone, or progestin and estrogen in combination (as found in 
OCs) on ovarian cancer prevalence in the hen.  We found that treatment with progestin 
alone and in combination with estrogen decreased the prevalence of ovarian cancer.  A 
significant risk reduction of 91% was observed in the group treated with progestin 
alone (risk ratio 0.0909: 95% confidence interval 0.0117-0.704) and 81% was 
observed in the group treated with progestin plus estrogen (risk ratio 0.1916: 95% 
confidence interval 0.043-0.864).  Ovulatory events were also significantly reduced in 
these treatment groups compared to control.  We found no effect of progestin, either 
alone or in combination with estrogen, on apoptosis in the ovary, indicating that this is 
not the mechanism responsible for the protective effect of progestin in the hen. Our 
results suggest that ovulation is related to the risk of ovarian cancer in hens and that 
other factors, such as hormones, more than likely modify this risk.  Our study supports 
the use of oral contraceptives to prevent ovarian cancer and further validates the hen 
as a suitable animal model to test chemoprevention strategies. 
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Introduction 
Ovarian cancer is the leading cause of reproductive cancer death in U.S. 
women.  This high mortality rate can be attributed to the fact that greater than 80% of 
women are diagnosed at late stages of the disease once tumors have metastasized.  The 
5-year survival rate is less than 30% at later stages, although this survival rate is 
greater than 90% for the ~15% of women diagnosed at earlier stages of the disease 
when the tumor is still confined to the ovary [1].  These data support the need for the 
development of early detection strategies of the disease.  Unfortunately, efforts to 
identify a widely acceptable screening strategy have thus far failed.  Chemopreventive 
agents, such as oral contraceptives, may decrease the number of deaths due to ovarian 
cancer.      
Epidemiologic studies have consistently shown that ovarian cancer risk is 
decreased in women who use oral contraceptives [2].  In fact, a recent study showed 
that oral contraceptive use is associated with a 20% decrease in relative risk of ovarian 
cancer for every 5 years of use and longer duration of use further decreases the risk 
[3].  Additionally, the risk is reduced for 30 years or more after use has ceased [3].  
Several mechanisms have been proposed to explain how oral contraceptives decrease 
the risk of ovarian cancer, including inhibition of ovulation, induction of apoptosis, 
and inhibition of proliferation [4].  Animal models can be used to test the efficacy and 
mechanism of action of chemopreventive agents. 
The hen is a suitable animal model to test chemoprevention strategies because 
the hen spontaneously develops ovarian cancer which resembles the disease in 
women.  Hens have a high incidence of ovarian cancer, and similar to women, this 
incidence increases with age [5].  The utility of the hen as a preclinical model of 
ovarian cancer has been tested in a number of studies.  One study reported that 
chicken ovarian tumors express antigens that are frequently expressed in human 
 80 
ovarian cancer as well as those that are useful as surrogate biomarker endpoints in 
chemoprevention trials [6].  Pilot studies have been conducted in the hen with putative 
chemopreventive agents including aspirin [7] and flaxseed [8].  An earlier study also 
tested the effect of medroxyprogesterone acetate (Depo-Provera), commonly used in 
progestin-only formulations of contraceptives, on ovarian cancer prevalence [9].  Hens 
treated with Depo-Provera exhibited a 15% reduction of risk of ovarian cancer 
compared to control hens [9]. 
We have previously shown that steroid hormone, particularly estrogen, 
signaling may play a role in ovarian tumorigenesis (Chapter 2).  Oral contraceptives 
are comprised of steroid hormones and are associated with decreased risk of ovarian 
cancer.  Therefore, our objective was to test the effect of progestin and estrogen 
together, as commonly delivered in “the pill”, as well as progestin and estrogen alone 
on ovarian cancer incidence in the hen.  We also investigated the effect of these 
treatments on apoptosis in normal hen ovaries. 
 
Materials and Methods 
Animals 
Single-comb White leghorn hens were individually caged with access to food 
and water ad libitum.  Hens were maintained on a 15h light and 9h dark schedule.  A 
total of 231 approximately one year-old hens were allocated to 4 treatment groups: 
control, progestin alone, estrogen alone, and progestin and estrogen combined.  Hens 
were treated as described below.  Egg production was monitored daily as a marker of 
ovulation and hens were weighed monthly.  Necropsies were performed on hens that 
died before experiment termination (n=71) as well as those that were euthanized by 
CO2 asphyxiation at the end of the experiment (n=160).  All animal procedures were 
approved by the Institutional Animal Care and Use Committee of Cornell University.    
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Treatments 
Hens in the progestin alone and the combination treatment groups were 
injected with 50 mg of medroxyprogesterone acetate (MPA; Spectrum Chemical, 
Gardena, CA) dissolved in 1 ml of sesame oil.  Initially, the hens were injected with 
100 mg as previously described [8] resulting in an almost complete cessation of egg 
production; however, due to adverse effects of this dose, the dose was cut in half.  
Compared to the 100 mg dose, 50 mg resulted in fewer deaths and still exhibited an 
effect on egg production (although to a lesser extent).  Hens in the estrogen alone and 
the combination treatment groups were implanted with 25 mg estradiol implants 
(Compudose 200; Elanco Animal Health, Indianapolis, IN) previously reported to be 
bioactive in the hen [10-13].  Control hens were injected with 1 mL of the sesame oil 
vehicle and implanted with an empty silastic tube.  Injections were administered into 
the breast muscle (i.m.) every 3-4 weeks.  Hens were administered a local anesthetic 
(bupivacaine; 5 mg/ml) between the wings where implants were inserted through an 
incision made with a scalpel.  The incision was closed using tissue adhesive 
(VetBond).  Control implants were inserted similarly.  Treatments were administered 
for 16 months similar to the previous study where MPA was administered to hens [9]. 
 
Tissue collection 
At necropsy, samples of ovary were placed in cassettes in formalin for paraffin 
embedding and hens were examined for presence of tumors within the peritoneal 
cavity (i.e. ovary, oviduct, and intestine) as well as for accumulation of ascites fluid.  
The paraffin embedded sections were cut and stained with hematoxylin and eosin 
(H&E).  Diagnosis of hens was made by gross observation and confirmed by analysis 
of the H&E stained sections by two independent observers, one of whom is an avian 
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pathologist (ELB).  Tumors identified in hens were subsequently staged as previously 
described [7]. 
 
Estradiol radioimmunoassay (RIA) 
Blood samples were collected from the wing vein of a subset of hens 30, 60, 
120, 180, and 360 days after the first implantation of estradiol or control implants.  
Plasma isolated from the blood samples was assayed for estradiol using the Coat-A-
Count estradiol RIA kit (Siemens, Los Angeles, CA).  All samples were assayed in 
duplicate.  The average intra-assay coefficient of variation was 22%. 
 
TUNEL assay 
DNA fragmentation in apoptotic cells on normal ovarian tissue sections from a 
subset of each treatment group (n=6 each) was assessed by using the ApopTag® Plus 
Peroxidase In Situ Apoptosis Detection Kit (Chemicon International, Billerica, MA) 
according to the manufacturer’s instructions.  Slides were scanned at 40X using the 
Aperio Scanscope (Aperio Inc., Vista, CA).  Twenty random images of ovarian 
surface epithelium (OSE) and thirty random images of the ovarian body for each hen 
were obtained using the ImageScope Viewer program (Aperio Inc., Vista, CA).  
Positive staining of apoptotic nuclei was quantified in the images using the color range 
function of Adobe Photoshop.  The intensity of positive staining was then graded on a 
scale from 0 to 3 (0=no staining; 1=low, 2=medium and 3=high intensity staining).   
 
Statistical analysis 
All tests were carried out using SAS version 9.2 with a significance level of 
p<0.05.  The effect of treatment on ovarian cancer incidence was analyzed using proc 
GENMOD as recommended by staff at the Cornell Statistical Consulting Unit.  Egg 
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production and plasma estradiol level among treatments were analyzed using proc 
MIXED.  The effect of treatment on apoptosis in the OSE and the ovarian body was 
analyzed using proc GLM. 
 
Results 
Health parameters 
A total of 71 out of 231 (31%) birds died before experiment termination (Table 
3.1).  A larger proportion of hens treated with MPA, either alone (37%) or in 
combination with estrogen (34%), died compared to the control (22%) or estrogen 
alone (30%) groups, however, we found no statistically significant effect of treatment 
on mortality.  The higher mortality in the hens treated with MPA may be due to the 
fact that a higher dose of MPA (100 mg) was utilized at the beginning of the 
experiment.  This dose was used in the Barnes et al study (2002) that also reported a 
higher mortality rate for hens treated with MPA (32%) compared to the control 
treatment [9].  The mechanism of this effect is unclear; however, MPA treatment can 
result in depression, polyuria, weight gain, liver damage and diabetes in birds [14].  
We also observed no significant effect of treatment on body weight (Figure 3.1).   
 
Table 3.1 Number of hens that died before experiment termination. 
 
Treatment Total hens Mortality (%) 
Control 59 13 (22) 
MPA+E2 56 19 (34) 
MPA 59 22 (37) 
E2 57 17 (30) 
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Figure 3.1 Effect of treatment on body weight (n=231).  Hens were weighed 
approximately every 4 weeks.  There was no effect of treatment on body weight.  Bars 
indicate standard deviation. 
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Gross examination of chicken ovaries 
Tumors in hens were identified grossly by the presence of firm, nodular 
outgrowths on the ovary, often accompanied by ascites and implants on the serosa of 
tissues within the abdominal cavity as described previously [5, 15-17].  Table 3.2 
summarizes the data obtained at necropsy for the hens diagnosed with cancer.  
Seventeen and 19 ovarian tumors out of the 25 diagnosed also involved the oviduct 
and the intestines, respectively.  There was a significant association of treatment with 
the presence of tumors in the intestine (p<0.02), but no association of treatment with 
oviductal tumors or ascites (Table 3.2).  We also found no significant effect of 
treatment on stage of ovarian cancer (Table 3.3), and the majority of the tumors were 
late stage (metastases present outside of the ovary, with or without ascites).  Hens 
were diagnosed at necropsy and confirmed by histology.  Three tumors (all in the 
control group) were identified as early stage after examination of the H&E stained 
section.  At necropsy, these ovaries had no visible signs of cancer, and two out of the 
three were regressed (no large or small yellow follicles present).   
 
 
Table 3.2 Number of hens with ovarian cancer that involved the oviduct, intestines 
and ascites accumulation. 
 
Treatment Oviduct (%) Intestine (%) Ascites (%) 
Control 6 (55) 6 (55) 3 (27) 
MPA+E2 2 (100) 2 (100)
a 
2 (100) 
MPA 1 (100) 0 (0) 0 (0) 
E2 8 (73) 11 (100)
a 
6 (55) 
a
 There is a significant increase in the number of hens with tumors  
involving the intestine compared to control (p<0.02) 
 86 
 
Table 3.3 Stage of ovarian cancer [7] for hens diagnosed with the disease. 
 
Treatment Stage 1 (%) Stage 2 (%) Stage 3 (%) Stage 4 (%) 
Control 3 (30) 0 (0) 4 (40) 3 (30) 
MPA+E2 0 (0) 0 (0) 0 (0) 2 (100) 
MPA 0 (0) 0 (0) 1 (100) 0 (0) 
E2 0 (0) 0 (0) 5 (45) 6 (55) 
 
Cancer prevalence 
We observed a significant effect of treatment on the prevalence of ovarian 
cancer (p<0.01; Table 3.4).  There was a 19% prevalence of ovarian cancer in the 
control group.  This is similar to the prevalence that has previously been reported (10-
23%) in hens at this age [7, 18].  Treatment with MPA alone (p<0.005) and in 
combination with estrogen (p<0.01) significantly decreased prevalence of ovarian 
cancer compared to the control group.  Administration of estrogen alone had no 
significant effect on cancer prevalence compared to the control treatment.  
 
Histological classification of ovarian tumors 
Microscopically, we identified three separate morphologies of tumors: 
endometrioid, serous, and “oviduct.”  Figure 3.2 illustrates examples of all three types.  
Endometrioid tumors resemble those found in women, and are generally solid with a 
dense stromal component.  They can exhibit glands (Figure 3.2A), as well as 
squamous differentiation.  Serous tumors also resemble those found in women and 
have very little stroma associated with the tumor cells (as opposed to endometrioid 
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tumors).  These tumors can have papillary projections (Figure 3.2B).  The third type, 
“oviduct”, does not have a tumor counterpart in women.  These tumors are associated 
with the production of secretory granules (Figure 3.2C) and resemble the oviduct in 
the chicken.  They may represent a subtype of the other two main types, but this is not 
clear at this time.  We found that hens treated with MPA, either alone or in 
combination with estrogen, did not develop the “oviduct” type of tumors (Table 3.5).  
In addition, there are a significantly greater number of hens with tumors that involve 
the intestines with serous type tumors compared to those with endometrioid type 
tumors (Table 3.6; p<0.05).   
 
Egg production 
Administration of MPA alone or in combination with estrogen significantly 
decreased egg production compared to the control treatment (p<0.01; Figure 3.3).  
There was no significant effect on egg production for the hens treated with estrogen 
alone compared to the control treatment.  
   
Table 3.4 Prevalence of ovarian cancer among treatments.  
 
Treatment Total hens Hens diagnosed with cancer (%) 
Control 59 11 (19)
 
MPA+E2 56 2 (4)
a 
MPA 59 1 (2)
b 
E2 57 11 (19)
 
a 
Decreased prevalence compared to control (p<0.01) 
b 
Decreased prevalence compared to control (p<0.005) 
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Plasma estradiol levels 
Hens treated with estrogen alone (p<0.01) or in combination with MPA 
(p<0.05) had significantly higher plasma estradiol levels compared to the control 
group (Figure 3.4).  As expected, treatment with MPA alone had no effect on plasma 
estradiol levels compared to the control treatment. 
 
TUNEL assay 
There was no significant effect of treatment on apoptosis in either the OSE 
(Figure 3.5A) or the ovarian body (Figure 3.5B) in normal (unaffected by ovarian 
cancer) hens. 
 
Discussion 
Our results suggest that ovulation is related to the incidence of ovarian cancer.  
We have shown that administration of progestin, either alone or in combination with 
estrogen, decreases ovarian cancer prevalence in the hen (Table 3.4).  In fact, 
treatment with progestin alone, or in combination with estrogen, significantly reduced 
the risk by 91% and 81%, respectively.  We also observed a significant reduction in 
ovulatory events (egg production) in hens treated with progestin alone or in 
combination with estrogen (Figure 3.3).  These results extend a previous study in the 
hen.  Barnes et al reported a 15% reduction in ovarian cancer risk in hens treated with 
MPA [9] and a significant decrease in egg production immediately after the progestin 
injection.  This reduction of egg production lasted for approximately 4 weeks.  It is 
possible that the marginal reduction in risk in the Barnes et al study (2002) was due to 
the fact that ovulation resumed for a significant portion of the experiment period.  In 
contrast, we observed a consistent reduction in egg production throughout the 
treatment period and a greater reduction in risk.  
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Figure 3.2 Representative H&E images of endometrioid (A), serous (B) and “oviduct” 
(C) types of chicken ovarian tumors.  Note the secretory granules in the “oviduct” type 
tumors (C; arrows).  Scale bar = 100µm.   
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Table 3.5 Histological subtypes of chicken ovarian tumors among treatments. 
 
Treatment Endometrioid (%) Serous (%) “Oviduct” (%) 
Control 5 (45) 1 (9)
 
5 (45) 
MPA+E2  1(50) 1 (50)
 
0 (0) 
MPA 1 (100) 0 (0)
 
0 (0) 
E2 3 (27) 4 (36)
 
4 (36) 
 
 
 
 
 
 
 
Table 3.6 Number of hens with ovarian cancer that involved the oviduct, intestines 
and ascites accumulation based on tumor subtype. 
 
Type Oviduct (%) Intestine (%) Ascites (%) 
Endometrioid 6 (60) 5 (50) 4 (40) 
Serous 4 (67) 6 (100)
a 
1 (11) 
Oviduct 7 (78) 8 (89) 5 (56) 
              
               a 
There is a significant increase in the number of hens with tumors that 
 
          involve the intestines in the serous subtype compared to the  
          endometrioid subtype (p<0.05) 
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Figure 3.3 Effect of treatment on egg production (n=231).  MPA+estrogen (P+E) or 
MPA (P) significantly decreased egg production compared to control (p<0.01).  There 
was no significant effect on egg production for the hens treated with estrogen (E) 
compared to control.  
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Figure 3.4 Effect of treatment on plasma estradiol levels (n=8-14 hens per treatment).  
E (p<0.01) or P+E (p<0.05) significantly elevated plasma estradiol levels compared to 
control.  Treatment with P had no effect on plasma estradiol levels compared to 
control. 
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Figure 3.5 Effect of treatment on apoptosis in the OSE (A) and the ovarian body (B).  
There was no significant effect of treatment on apoptosis in the OSE or the ovarian 
body (n=6 per treatment). 
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Hormones are thought to affect the development and/or progression of ovarian 
cancer.  Progesterone has been proposed to protect against ovarian tumor development 
[19].  This protective effect might be independent of the effect of progestin on 
ovulation.  Interestingly, women on progestin-only formulations of oral contraceptives 
are also at reduced risk of ovarian cancer even though ovulation is only suppressed in 
about 40% of users [20].  In vitro studies have shown that progesterone inhibits cell 
growth and induces apoptosis in ovarian cancer cell lines [4], as well as inhibits 
growth of normal OSE [21].   One study reported that monkeys treated with a 
progestin exhibited increased apoptosis in the OSE compared to control and ethinyl-
estradiol treated monkeys [22]. These studies suggest that the apoptotic effects of 
progestin might explain the protective effect observed with oral contraceptive use.  In 
our study, however, we did not find a significant effect of progestin on apoptosis in the 
OSE (Figure 3.5A) or the ovarian body (Figure 3.5B) from normal hens.  Therefore, it 
appears that, in the hen, induction of apoptosis does not account for the protective 
effect observed, although other mechanisms of progestin action may be involved.   In 
addition to effects on apoptosis, progestins are also thought to affect proliferation, 
differentiation and invasiveness of cancer cells [23].  Further studies are needed to 
determine the mechanism of progestin action in the hen. 
Interestingly, it appears that progestin administration hindered the development 
of tumors we have classified as “oviduct” type (Table 3.5).  These tumors resemble 
normal chicken oviduct and are characterized by the presence of large amounts of 
secretory granules (Figure 3.2C). They may represent subtypes of the endometrioid or 
serous types also identified, higher degrees of tumor differentiation, or an alternative 
site of origin (like the oviduct).  We observed nodules on the oviduct for seven out of 
the nine (78%) birds with the “oviduct” subtype, and this was similar to the percentage 
of hens with oviductal nodules in the other two subtype groups (Table 3.6).  Since 
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most of the hens had ovarian tumors with involvement of the oviduct, it is not clear 
whether the tumors in any of the particular subtypes originated in the oviduct and then 
spread to the ovary.  It should be noted that morphology alone is not sufficient to type 
ovarian tumors.  Pathologists also use immunohistochemistry for molecular markers 
such as estrogen receptors, p53 and WT1 to distinguish between the subtypes [24, 25].  
A similar approach could be taken to determine whether the “oviduct” type tumors are 
subtypes of the endometrioid and serous ovarian tumors in the hen.  In contrast to 
other studies in the hen which identified all of the four ovarian tumor subtypes seen in 
women [15, 16, 26] we did not observe clear cell or mucinous tumors.  This may 
reflect a strain-dependent susceptibility to different types of tumors, similar to the 
observation that some strains have a higher prevalence of ovarian cancer [7].  In 
addition, associations for some ovarian cancer risk factors differ by subtype in women 
[27], and this may be the case in hens as well.  The high prevalence of endometrioid 
and serous tumors in the hen, make it a good model to study the etiology and 
progression of these subtypes.    
In contrast to progesterone, estrogens are thought to promote ovarian tumor 
progression [28].  Studies have shown that women who undergo estrogen-only 
hormone replacement therapy have an increased risk of developing ovarian cancer 
[29-31].  In the current study, hens treated with estrogen (either alone or in 
combination with progestin) exhibited significantly increased plasma estradiol levels 
compared to control hens (Figure 3.4), but there was no effect of estrogen treatment on 
cancer prevalence (Table 3.4).  We did, however, observe a significant increase in the 
number of hens with tumors that involved the intestines with estrogen treatment, either 
alone or in combination with MPA (Table 3.2).  In addition, although not significant, a 
larger percentage of hens treated with estrogen exhibited serous type tumors (83%) 
versus hens that were not treated with estrogen (17%; Table 3.5).  In humans, serous 
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tumors are considered more aggressive than the other subtypes and the association of 
estrogen treatment with intestinal nodules and the serous subtype suggests that 
estrogen may promote tumor progression in the hen.  These results are similar to those 
seen in a recent study where exogenous estrogen was shown to accelerate the onset of 
ovarian tumor development and decrease survival in a mouse model of the disease 
[32].  Although we did not directly measure tumor onset in the current study, hens 
treated with estrogen alone exhibit a decline in egg production before the hens in the 
control group (Figure 3.3).  Egg production has been shown to decline in hens with 
ovarian cancer [7] and it is possible that this decline in egg production signifies an 
earlier onset of the disease in these hens.  Interestingly, we observed pre-neoplastic 
lesions in H&E sections from three hens treated with the combination of MPA and 
estrogen, but none in the other treatment groups, further supporting a role for estrogen 
in ovarian tumor progression (data not shown).  Estrogens have been shown to 
promote cellular proliferation and inhibit apoptosis in ovarian cancer cells [23].  
Similar to our results with progestin alone, we did not observe an effect of estrogen on 
apoptosis in the OSE (Figure 3.5A) or the ovarian body (Figure 3.5B) from normal 
hens.  In our previous study (Chapter 2), we identified estrogen-regulated genes that 
are over-expressed in chicken ovarian tumors.  Those results, combined with this 
current study, suggest that estrogen affects the progression of ovarian cancer in the 
hen.   
Another study from our lab indicated an association between the number of 
ovulatory events and the risk of ovarian cancer.  Giles et al reported a decreased 
incidence of ovarian cancer in restricted ovulator (RO) hens compared to wild-type 
(WT) hens [17].  RO hens have a mutation that affects their ability to incorporate yolk 
into the developing follicle and consequently ovulate significantly fewer times than 
their WT counterparts [33].  Interestingly, RO hens have a hormone profile associated 
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with high risk of ovarian cancer (low progesterone, high estrogen; [34, 35]) further 
suggesting that ovulation is linked to ovarian cancer risk.  There was no difference, 
however, in overall ovulation rate between WT hens that were diagnosed with ovarian 
cancer versus normal WT hens [17].  This is similar to a previous report in the hen 
suggesting that ovulation rate was not the differentiating factor in high producing hens 
experiencing very frequent ovulatory events [5].  In the current study, we also did not 
find a significant difference in overall egg production in hens that did or not have 
ovarian cancer within the control group (data not shown).  These findings suggest that 
other factors may modify the risk of ovarian cancer. 
In the 1970’s Fathalla proposed the “incessant ovulation” hypothesis [36].  
This hypothesis is based on the idea that ovulation results in the repeated rupture and 
repair of the OSE.  Over time, this cyclical damage could result in genetic mutations 
that predispose these cells to become cancerous.  Women with high lifetime ovulation 
numbers would therefore have an increased risk of developing ovarian cancer.  
Epidemiological studies in women support this hypothesis.  Pregnancy and oral 
contraceptive use are associated with decreased risk of ovarian cancer and both reduce 
the number of ovulatory events [37].  Our results in the hen also support this 
hypothesis since oral contraceptives (progestin alone or combined with estrogen) 
decreased the prevalence of ovarian cancer as well as egg production.  Other studies in 
the hen have tested alternative chemopreventive agents, including aspirin [7] and 
flaxseed [8].  Administration of these agents resulted in a decrease in ovarian cancer 
stage, but no difference in prevalence.  Interestingly, no effect on egg production was 
observed with these agents.  This is in contrast to the significant decrease of ovarian 
cancer prevalence and egg production with progestin treatment, but no effect on stage.  
Our results indicate that ovulatory events might set the level of risk of the disease and 
other factors (such as hormones) may modulate this risk.  Importantly, our results 
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support the use of oral contraceptives as chemopreventive agents for ovarian cancer, 
as well as the use of the hen as a model for chemoprevention research. 
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CHAPTER 4 
 
CHARACTERIZATION OF ESTROGEN RECEPTOR EXPRESSION IN AN 
ANIMAL MODEL OF OVARIAN CANCER 
Abstract 
There is growing evidence that estrogens may promote tumor progression, 
including ovarian tumors.  Studies have shown that hens develop ovarian cancer 
spontaneously, therefore providing a suitable animal model for the disease.  We have 
previously shown that estrogen-dependent genes are up-regulated in chicken ovarian 
tumors and that estrogen modulates tumor progression.  Estrogens exert their actions 
in tissues through two different receptor subtypes (ESR1 and ESR2); therefore, our 
aim was to determine the expression of mRNA and protein for the estrogen receptor 
subtypes in ovaries of normal hens and ovaries from hens with ovarian cancer.  
Quantitative real-time PCR results showed that the relative mRNA expression of 
ESR1 and the ratio of ESR1/ESR2 are significantly greater, while relative ESR2 
mRNA expression tended to be decreased in tissue from hens with ovarian cancer 
when compared to normal ovarian tissue.  We also found differential ESR2 expression 
by tumor subtype in hens with metastatic cancer.  By Western blot, we detected a 
single main transcript for chicken ESR1 and chicken ESR2 at approximately the 
expected size in normal ovarian tissue and tissue from hens with ovarian cancer.  
Immunohistochemical analysis showed abundant ESR1 in tumor tissue and limited 
ESR2 protein expression in tumors as compared to normal.  Finally, we did not find a 
significant difference in plasma estradiol levels between normal hens and hens with 
ovarian cancer.  These results suggest that, in the hen, ESR1 may be mediating a 
proliferative response in ovarian cancer cells.  This similarity to human ovarian cancer 
supports the utility of the hen for testing possible endocrine therapies. 
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Introduction 
Ovarian cancer is the leading cause of death due to gynecologic cancer in the 
United States and the fifth leading cause of cancer death among U.S. women.  The 
American Cancer Society estimates that approximately 21,880 women in the U.S. will 
be diagnosed with ovarian cancer in 2010.  Furthermore, ovarian cancer will account 
for more than 13,850 deaths among U.S. women in 2010.  Currently, only 20% of 
cases are diagnosed at an early stage.  If ovarian cancer is detected and treated early, 
the five-year survival rate is greater than 90%.  The fact that most ovarian cancers are 
diagnosed at later stages illustrates our lack of understanding of the etiology of the 
disease.  This may be due, in part, to the limited availability of a suitable animal model 
for ovarian cancer.   
One animal model, the domestic hen, has been shown to spontaneously 
develop ovarian cancer [1, 2].  Fredrickson (1987) found that approximately 24% of 
466 hens developed malignant ovarian adenocarcinomas.  He also observed that tumor 
development was age-dependent and uncommon in birds less than 2 years of age.  We 
have also observed an increase in percentage of birds with ovarian cancer after 2 years 
of age [2].  Furthermore, hen tumors are positive for antibodies frequently used to 
characterize human ovarian tumors, including some useful in chemoprevention trials 
[3].  A previous study from our lab has also shown expression of an oviductal protein 
in hen ovarian tumors, suggesting that these tumors acquire characteristics of 
Müllerian-duct derived epithelia, similar to serous ovarian adenocarcinoma in women 
[4].  The hen thus provides a suitable animal model for the study of ovarian cancer.  
Although the molecular mechanisms of ovarian cancer remain unclear, there is 
growing evidence that estrogens may be involved in tumor progression.  Estrogens 
directly promote proliferation in ER positive ovarian cancer cell lines [5-7], with 
effects possibly being associated with cellular levels of estrogen receptors [5].    More 
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recently, one study confirmed that ovarian cancer cell lines with functional ER are 
growth responsive to estrogen and that estradiol mediates expression changes in genes 
that regulate the cell cycle, apoptosis, transcription and signaling [8].  Epidemiological 
evidence also suggests that estrogens may promote ovarian cancer in women on 
hormone replacement therapy, possibly due to persistently elevated estrogen levels 
[9].  These lines of evidence point to a possible role of estrogen in ovarian cancer in 
women.   
Estrogen can exert effects on target tissues through interaction with estrogen 
receptors.  There are two subtypes of the estrogen receptor (ESR1 and ESR2) encoded 
by separate genes, that are expressed in a tissue specific manner and thought to 
regulate differential gene functions.  Interestingly, some studies have shown that the 
loss of ESR2 may be a common step in estrogen dependent ovarian tumor progression 
[10, 11].  Increased expression of ESR1 [10, 11] and an increase in the ratio of 
ESR1/ESR2 are also associated with tumor progression [12-14].  It is thought that 
ESR1 and ESR2 regulate opposing cellular functions, with ESR1 involved in cellular 
proliferation and ESR2 mediating growth inhibition.  There may be a balance of 
factors that regulates cellular growth because normal rat and human ovarian cells 
express greater amounts of ESR2 and less ESR1 [15].  In tumor cells, however, this 
balance is disrupted and cells are allowed to proliferate abnormally [15].  The 
importance of this disruption is evident in a recent study which reported that ESR1, 
but not ESR2, mediates estrogen-driven growth of epithelial ovarian cancer [8]. 
Combined, these studies lend support to the idea that the relative levels of ESR1 and 
ESR2 may be important regulators of cell growth.       
  To date, no studies have addressed estrogen receptor subtype mRNA and 
protein expression in ovarian cancer of the hen, the only animal model that develops a 
high incidence of the disease spontaneously.  Our objective was to determine mRNA 
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and protein expression of ESR1 and ESR2 in normal ovarian tissue samples and tissue 
samples from hens with ovarian cancer.  We also determined whether there were 
differences in plasma estradiol levels of normal hens and hens with ovarian cancer. 
 
Materials and Methods 
Tissue Samples 
Normal ovarian (n=11) and ovarian tumor (n=13) tissue samples from 2-5 
year-old White leghorn hens were collected and stored in RNAlater (Ambion, Inc., 
Austin, TX) for real-time PCR analysis or were fixed and paraffin-embedded and used 
for immunohistochemistry.  Normal oviduct tissue samples from a 3 year-old White 
leghorn hen was also collected, paraffin-embedded, and used as a positive control for 
immunohistochemistry.  Blood samples from a subset of the normal hens (n=8) and 
hens with ovarian cancer (n=11) used for real-time PCR and immunohistochemistry, 
were collected at the time of tissue collection for radioimmunoassay (RIA) analysis of 
plasma levels of estradiol.  Ovarian and oviduct tissue was collected from 3-4 year-old 
White leghorn hens, frozen on dry ice, and used as a control for Western blot analysis.  
Diagnosis was made by gross observation and confirmed by histological analysis of 
hematoxylin and eosin (H&E) stained sections.  The H&E stained sections were also 
used to categorize the tumors based on the three types we have previously identified 
(unpublished data).  These types include endometrioid tumors which are solid, with a 
dense stromal component, serous tumors with very little stroma associated with the 
tumor cells, and “oviduct” tumors that are associated with the production of secretory 
granules and resemble normal chicken oviduct.  All animal procedures were approved 
by the Institutional Animal Care and Use Committee of Cornell University. 
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Real-time quantitative PCR 
RNA was extracted from hen ovarian tissue using the RNeasy Mini kit 
(Qiagen, Valencia, CA) and RNA integrity was verified using the 2100 Expert 
Bioanalyzer (Agilent Technologies, Santa Clara, CA).  Extracted RNA was reverse-
transcribed into cDNA and the cDNA was used for quantitative PCR to determine 
mRNA expression levels of ESR1 and ESR2 relative to the internal control, ribosomal 
RNA (18S).  Chicken specific Taqman primers and probes for ESR1 (GenBank 
accession #NM_205183) and ESR2 (GenBank accession #NM_204794) were 
designed using Primer Express software v2.0 from Applied Biosystems.  The ESR1 
primers defined a cDNA of 79 bp (forward: 5‟ CAGCATTCGTGAGAGGATGTCTA 
3‟; reverse: 5‟ ACAGTACCGGGTCTCCTTGGT 3‟; probe: 6FAM 
TACCAATGAGAAAGGGAGCCTGTCCATG MGBNFQ) and the ESR2 primers 
defined a cDNA of 111 bp (forward: 5‟ GGAAATGCTATGAAGTGGGA ATG 3‟; 
reverse: 5‟ TCTTGGTTTTGCCCATGCA 3‟; probe 6FAM TGGGTATCGAAT 
CCTGCGCC MGBNFQ).  Taqman primers and probes for 18S (Applied Biosystems, 
Foster City, CA) were used as control and run for each sample.  Total volume of 
reactions was 50 μL with a final concentration of 1X TaqMan Universal PCR Master 
Mix (Applied Biosystems, Foster City, CA), 900 nM of ER primer pairs (ESR1+2), 50 
nM of 18S primer pair, and each respective TaqMan probe (at 250 nM of ER probes 
(ESR1+2) and 200 nM of 18S probe).  Control reactions containing no template and 
reactions lacking reverse transcriptase were also run.  All sample reactions were run in 
duplicate using the ABI Prism 7000 Sequence Detection System.  Mean values of 
estrogen receptor subtype mRNA were calculated relative to 18S reactions (also run in 
duplicate).  The relative amount of mRNA in a particular sample was determined by 
the comparative threshold cycle (CT) method using Sequence Detection System 
Software (Applied Biosystems, Foster City, CA).          
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SDS-PAGE and Western blot  
Frozen normal (n=3) and tumor (n=3) ovarian tissue samples were 
homogenized in lysis buffer (10 mM Tris pH 7.5, 1.0% Triton x-100, 150 mM NaCl, 1 
mM EGTA, and protease inhibitors) and centrifuged.  The supernatant was collected 
for SDS-PAGE and protein concentration was determined using the BCA protein 
assay (Pierce Biotechnologies, Rockford, IL).  Approximately 25 ug of protein from 
ovarian tissue samples was added to sample buffer and samples, including 25 ug of 
protein from oviduct as a positive control, were loaded onto 10% Tris-HCl gels 
(Pierce Biotechnologies, Rockford, IL) and run under denaturing conditions at 100V 
for 50 minutes. The separated proteins were transferred to a nitrocellulose membrane 
(Pierce Biotechnologies, Rockford, IL) and blocked for 30 minutes in 1X TBST + 5% 
non-fat milk.  Membranes were incubated in rabbit polyclonal ESR1 antibody against 
the N-terminal epitope of human ESR1 (described in 21; kindly provided by Dr. W.L. 
Kraus of Cornell University) at a dilution of 1:10,000 for 2 h, followed by incubation 
in HRP-conjugated goat anti-rabbit IgG (Molecular Probes, Eugene, OR) at a dilution 
of 1:10,000 for 1 h prior to detection of specific protein through enhanced 
chemiluminescence with LumiGLO (KPL, Gaithersburg, MD).  Membranes were 
stripped in stripping solution (1M Tris-HCl pH 6.7, 10% SDS, -mercaptoethanol, and 
water) and processed as described above to examine ESR2.  The rabbit polyclonal 
ESR2 antibody was made against the N-terminal epitope of human ESR2 (kindly 
provided by Dr. W.L. Kraus of Cornell University) and used at a dilution of 1:10,000 
for 2 h, followed by incubation in HRP-conjugated goat anti-rabbit IgG (KPL, 
Gaithersburg, MD) at a dilution of 1:10,000 for 1 h.  SDS-PAGE and Western blot 
were performed in duplicate.      
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Immunohistochemistry 
Paraffin sections were deparaffinized and rehydrated through a series of 
treatments with xylene and ethanol.  Sections were boiled in citrate buffer for antigen 
retrieval and blocked in 10% goat serum in PBS for 30 minutes.  Sections were then 
incubated with the polyclonal ESR1 antibody (described above) at a dilution of 1:100 
or the polyclonal ESR2 antibody (described above) at a dilution of 1:50 for 1 h at 
39˚C.  Control slides were incubated with rabbit IgG at a dilution of 1:100 or 1:50, 
respectively.  Incubation with primary antibody (or control IgG) was followed by 
incubation in AlexaFluor 488 goat anti-rabbit IgG secondary antibody (1 g/mL) for 1 
h at 39˚C.  Slides were viewed using a Nikon eclipse E600 microscope with 
fluorescence capability and images were captured with a Spot RT Slider camera at the 
same exposure in each figure. 
 
Estradiol radioimmunoassay (RIA) 
Plasma isolated from blood samples was assayed for estradiol using the Coat-
A-Count estradiol RIA kit (DPC, Los Angeles, CA).  All samples were assayed in 
duplicate.  The intra-assay coefficient of variation was 3.9%.  
 
Statistics   
Data were analyzed for significance with SAS using proc GLM with a 
significance level of P < 0.05.  Duncan‟s multiple range tests were used to analyze 
means.   
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Results 
Real-time quantitative PCR 
Figures 4.1A and 4.1B show data for real-time quantitative PCR for ESR1 and 
ESR2, respectively.  Results indicate that ESR1mRNA expression is significantly 
increased in ovarian tumor samples as compared to normal ovarian samples (P < 
0.01).  There is a trend for ESR2 mRNA to be decreased in ovarian tumor samples as 
compared to normal ovarian samples, however this difference was not significant (P = 
0.07).  Figure 4.1C shows that the ratio of ESR1/ERSR2 mRNA expression is 
significantly higher in ovarian tumor samples as compared to normal ovarian samples 
(P < 0.02). 
Figure 4.2 shows ESR2 mRNA expression across for the three ovarian tumor 
subtypes previously identified by our lab: endometrioid, serous, and “oviduct”.  We 
found that there is significantly more ESR2 expression in “oviduct” tumors compared 
to endometrioid and serous tumors (p<0.05).  There was no difference in ESR1 
expression by tumor subtype.   
 
Western blot and immunohistochemistry 
Figure 4.3A is a representative Western blot of ESR1 protein expression.  A 
primary band appears close to the expected size (~67 kDa) in ovarian tissue samples 
from hens (lanes 1 and 2), as well as the positive control (oviduct; lane 3).  Figure 
4.3B illustrates representative immunohistochemistry results using the ESR1 antibody 
and the IgG control.  Panels A, B, and C are hematoxylin and eosin (H&E) stained 
sections of oviduct tissue, normal ovarian tissue and tumor ovarian tissue, 
respectively.  There is ESR1 expression in the oviduct tissue in the epithelial cells and 
in the cells of the tubular glands (Panel D arrows).  There is also ESR1 protein  
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Figure 4.1 Estrogen receptor mRNA expression in ovaries with tumors (n=13) and 
normal ovaries (n=11). A. ESR1 mRNA expression.  Asterisks indicate a significant 
increase in ovaries with tumors as compared to normal ovaries (p < 0.01).  B. ESR2 
mRNA expression.  No significant difference was found (p = 0.07).  C. Ratio of 
ESR1/ESR2 mRNA expression.   Asterisks indicate a significant increase in ovaries 
with tumors as compared to normal ovaries (p < 0.02).  Bars indicate mean ± standard 
error. 
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Figure 4.2 ESR2 mRNA expression in endometrioid, serous and “oviduct” tumors.  
Different letters indicate significant differences (p<0.05).  Bars indicate standard error.   
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expression in the stroma and theca of normal ovarian tissue (Panel E arrows).  ESR1 
protein expression is seen in ovarian tissue from hens with ovarian cancer, especially 
in the nests of tumor cells (Panel F arrows).  Arrowheads in panels D-I indicate 
autofluorescence.  Panels G, H, and I are rabbit IgG controls for oviduct tissue, normal 
ovarian tissue, and tumor ovarian tissue, respectively.  There is no specific staining 
evident in these sections, although there is some autofluorescence associated with red 
blood cells (arrowheads).   
Figure 4.4A shows a representative Western blot of ESR2 protein expression.  
There is a single band at slightly higher than the expected size (~55 kDa) in ovarian 
tissue samples from hens (lanes 1 and 2), and in the positive control (oviduct; lane 3).    
Figure 4.4B illustrates representative immunohistochemistry results using the ESR2 
antibody and the IgG control.  Panels A, B, and C are H&E stained sections of oviduct 
tissue, normal ovarian tissue, and tumor ovarian tissue, respectively.  There is ESR2 
protein expression in the oviduct tissue restricted to the epithelial cells (Panel D 
arrows).  ESR2 protein expression is seen in the stroma and granulosa cells of normal 
ovarian tissue (Panel E arrows).  Limited ESR2 protein expression is seen in the 
stroma or glandular areas in the ovary of the hens with cancer (Panel F).  Arrowheads 
in panels D-I indicate autofluorescence.  Panels G, H, and I are rabbit IgG controls for 
oviduct tissue, normal ovarian tissue, and tumor ovarian tissue, respectively.  Once 
again, there is no specific staining evident in these sections, although some 
autofluorescence of red blood cells is seen (arrowheads).   
 
Estradiol radioimmunoassay (RIA) 
Figure 4.5 shows that plasma estradiol levels are not significantly different 
between normal hens and hens with ovarian cancer (p = 0.45).  
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Figure 4.3 There is abundant ESR1 protein expression in chicken ovarian tumor 
tissue.  A. Western blot of chicken ovarian tissue and oviduct confirming specificity of 
the antibody.  B. Immunohistochemistry with ESR1 antibody.  H&E staining of 
oviduct tissue (A), normal ovarian tissue (B) and ovarian tissue from hen with cancer 
(C); ESR1 staining of oviduct tissue (D), normal ovarian tissue (E) and ovarian tissue 
from hen with cancer (F); Negative control (rabbit IgG) of oviduct tissue (G), normal 
ovarian tissue (H) and ovarian tissue from hen with cancer (I).    Arrows indicate 
specific staining and arrowheads indicate autofluorescence.  Scale bar = 100 μm.   
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Figure 4.4 There is little to no expression of ESR2 protein expression in chicken 
ovarian tumor tissue.  A. Western blot of chicken ovarian tissue and oviduct 
confirming specificity of the antibody.  B. Immunohistochemistry with ESR2 
antibody.  H&E staining of oviduct tissue (A), normal ovarian tissue (B) and ovarian 
tissue from hen with cancer (C); ESR2 staining of oviduct tissue (D), normal ovarian 
tissue (E) and ovarian tissue from hens with cancer (F); Negative control (rabbit IgG) 
of oviduct tissue (G), normal ovarian tissue (H) and ovarian tissue from hen with 
cancer (I).  Arrows indicate specific staining and arrowheads indicate 
autofluorescence.  Scale bar = 100 μm.  
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Figure 4.5 Plasma estradiol level of normal hens (n=8) and hens with ovarian cancer 
(n=11).  No significant difference was found (P = 0.45).  Bars indicate mean ± 
standard error. 
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Discussion 
Our data indicate that ESR1 mRNA is significantly increased in ovaries from 
hens with ovarian cancer as compared to those from normal hens.  This result has been 
seen in similar studies utilizing ovarian cancer tissue samples from women [10, 11].  
Studies in women have also shown a significant decrease in ESR2 mRNA in ovarian 
tissue from women with ovarian cancer [11-13].  There is a trend toward decreased 
ESR2 mRNA in ovarian tissue from hens with ovarian cancer as compared to tissue 
from normal hens, but this trend does not reach significance.  Our data also reveal that 
the ratio of ESR1/ESR2 mRNA is significantly increased in ovarian tissue from hens 
with cancer compared to tissue from normal hens.  This result is similar to what has 
been previously reported in women [13, 14]. 
Estrogen receptor expression has been reported to be variable based on tumor 
subtype, with higher expression in serous and endometrioid subtypes [16-18].  We 
have observed a difference in ESR2 mRNA expression based on tumor subtype, with 
greater expression in “oviduct” tumors compared to endometrioid and serous types in 
hens with metastatic disease.  This result is interesting because ESR2 expression is 
associated with longer disease-free survival and overall survival in women with 
ovarian cancer [19].  In addition, ESR2 has been shown to be a predictor of response 
to therapy in breast cancer [20].  These results suggest that “oviduct” tumors in the 
hen may be more responsive to endocrine therapies.  Further characterization of this 
subtype is needed; however, it is clear that ovarian cancer subtypes and grades exhibit 
differences in receptor expression levels that may be exploited when developing 
therapeutic strategies. 
It should be noted that estrogen receptors in the chicken are structurally and 
functionally similar to those in the human.  According to UniGene, chicken ESR1 
protein is ~79% similar to human ESR1, while chicken ESR2 protein is ~78% similar 
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to human ESR2.  Human ESR1 and chicken ESR1 share three regions of high 
homology that are most likely crucial for receptor function.  These regions are the 
DNA-binding domain (100% homology), transcription activation domain (87% 
homology), and ligand-binding domain (94% homology) [21].  A conserved domain 
search through NCBI also identifies conserved domains of chicken ESR2 for ligand-
binding and DNA-binding [22].  These conserved regions suggest that transcriptional 
action and regulation are similar between human and chicken estrogen receptor 
subtypes.  This is an important consideration when using the hen to study the role of 
estrogen/estrogen receptor signaling in ovarian cancer because the different receptor 
subtypes signal in unique ways dictated by their interaction with different co-
activators and co-repressors.  Sequence similarity between human and chicken 
estrogen receptor subtypes suggest that these unique interactions would be conserved 
in the chicken.   
Western blot analysis indicates that our ER antibodies each detect one main 
band at the approximate expected size in hen ovarian lysates.  Moreover, these 
heterologous antibodies stain oviduct samples differentially in accordance with the 
known distribution of ESR1 in avian oviduct [23, 24].  Our immunohistochemistry 
analysis illustrates the expression of ESR1 and ESR2 protein in the chicken.  ESR1 
and ESR2 protein expression is primarily nuclear, although some cytoplasmic 
expression is also seen (data not shown).  Although estrogen receptor protein 
expression in normal ovarian tissue and tissue from hens with cancer was not 
quantified, ESR1 protein expression was widespread throughout the glandular areas 
comprised of tumor cells in the ovaries from hens with cancer.  We observed limited 
ESR2 protein expression in ovaries from hens with cancer.  These results are 
consistent with what is seen in humans. 
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We performed RIA analysis to determine whether estradiol levels may be 
regulating the increase in ESR1 mRNA and protein in hens with ovarian cancer.  It is 
possible that estrogen may upregulate its receptor.  We found no significant difference 
in plasma estradiol levels between normal hens and hens with ovarian cancer although 
we cannot completely rule out the possibility that estradiol does regulate ESR1 
because of the variation in estradiol levels seen in our sample population.  This 
variation is due to the fact that hens may have been at different points of their 
ovulatory cycle when they were euthanized.  Estradiol levels fluctuate throughout the 
cycle, and increase 4-6 hours before the hen ovulates [25].  One would expect laying 
hens to have higher basal levels of circulating estradiol than non-laying hens.  In fact, 
because they were older hens, only 38% (3/8) of normal birds were laying, while 9% 
(1/11) of the hens with ovarian cancer were ovulating.  Our data would suggest that 
hens with ovarian cancer have a disproportionately higher level of plasma estradiol 
considering that a smaller percentage was ovulating when compared to normal hens.  
Our study is the first to show mRNA and protein expression of estrogen 
receptor subtypes in ovarian cancer of the hen.  We find ESR1 mRNA levels are 
significantly increased in ovarian tissue from hens with ovarian cancer as compared to 
tissue from normal hens.  We also observed a non-significant decrease in ESR2 
mRNA expression in tumors, suggesting that a possible role of ESR2 in ovarian 
cancer cannot be ruled out.  It has been shown that ESR2 inhibits estradiol-stimulated 
breast cancer cell proliferation [26].  ESR2 is thought to play a protective role against 
the mitogenic activity of ESR1 [27] and has been proposed to be a possible tumor 
suppressor in ovarian carcinogenesis [28].    Interestingly, one study reported that 
ESR2 may modulate the transcriptional activity of ESR1, suggesting that the relative 
expression levels of these subtypes may determine cellular responses to agonists and 
antagonists [29].  The fact that we see a trend of decreased ESR2 mRNA lends support 
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to the idea that the decrease/loss of ESR2 might be important in ovarian 
carcinogenesis.   
Due to the complicated nature of estrogen receptor signaling, it is clear that 
further studies investigating the role and nature of ESR1 in ovarian cancer are 
warranted.  We have previously shown that estrogen-dependent genes are up-regulated 
in chicken ovarian tumors (Chapter 2) and that exogenous estrogen modulates tumor 
progression (Chapter 3).  These studies, combined with the altered estrogen receptor 
subtype expression reported here highlight the importance of estrogen/estrogen 
receptor signaling in ovarian cancer of the hen.  The similarity of the spontaneous hen 
model to human ovarian cancer with respect to ER suggests that this animal model 
may be useful for testing endocrine therapeutics that could be helpful in combating 
this disease.     
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CHAPTER 5 
SUMMARY AND CONCLUSIONS 
  
We provide evidence that ovulation is important for the initiation of ovarian 
cancer, and that tumors possibly arise from the epithelial cells of the oviduct.  
Furthermore, our studies support a role for steroid hormones, particularly estrogen, in 
mediating the progression of the disease.  Figure 5.1 incorporates these data into a 
model for ovarian tumor development and progression of ovarian cancer of the hen.   
Ovulatory events are important for the initiation of ovarian tumor development 
in the hen.  We (Chapter 3) and others [1, 2] have shown that suppression of ovulation 
is associated with a decreased risk of the disease.  Furthermore, other 
chemoprevention studies in the hen showed no reduction in the prevalence of ovarian 
cancer when there was no decrease in egg production, although there was a decrease in 
stage (progression) of the disease [3, 4].  Ovulation itself has been described as a pro-
inflammatory process characterized by the local production and global recruitment of 
inflammatory factors to the site of ovulation [5].  These inflammatory factors are 
proposed to be mutagenic for OSE [6]; however, epithelial cells of the oviduct (either 
the fallopian tube in women or the infundibulum in chickens) can also be affected by 
these factors [5].  Figure 5.1A and Figure 5.1B illustrate the effect of ovulation on the 
oviduct epithelium and OSE, respectively.   
In humans, high grade ovarian tumors exhibit mutations in p53 [7] and are 
hypothesized to originate in the fallopian tubes [8].  Interestingly, hen ovarian tumors 
also exhibit p53 mutations, suggesting that tumors in the hen may arise from the 
oviduct as well [9].   Our microarray analysis (Chapter 2) provides further support for 
an alternative site of origin of chicken ovarian tumors.  We found that chicken ovarian           
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Figure 5.1 Model of ovarian tumor development and progression in the hen. 
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tumors express oviduct-related genes and that early stage ovarian tumors, but not 
OSE, express oviduct-related genes.  If the oviduct is a site of origin, it is possible that 
inflammatory factors produced during ovulation induce mutations in p53 in oviduct 
epithelial cells (Figure 5.1A).  These cells can then become incorporated into the 
ovary due to the intimate association between the infundibulum and ovarian surface, 
resulting in the development of an ovarian tumor (Figure 5.1A).  Alternatively, 
inflammatory factors may induce mutations of genes, such as Kras and Braf (as seen 
in women) [7], which result in the de-differentiation of OSE and the formation of an 
ovarian tumor (Figure 5.1B).  Cessation of ovulation could therefore reduce the local 
inflammatory reaction, possibly resulting in decreased formation of precursor lesions 
in the oviduct (or the de-differentiation of OSE) and a concomitant decreased 
prevalence of ovarian cancer.   
Once ovarian cancer has developed, hormones, particularly estrogen, may 
modulate the growth of ovarian tumors.  Tumor cells express estrogen receptors, in 
particular ESR1, and become responsive to estrogen produced locally in the ovary.  
Estrogen/estrogen receptor signaling can then mediate downstream effects such as 
proliferation, apoptosis, metastasis and invasion.  We have shown increased 
expression of Esr1 in chicken ovarian tumors compared to normal ovary (Chapter 4) 
and in early stage tumors compared to the surrounding stroma (Chapter 2).  
Interestingly, estrogen is thought to mediate its growth stimulatory effects through 
ESR1 [10].  We have also shown that estrogen-regulated oviduct-related genes are up-
regulated in chicken ovarian tumors, even at early stages (Chapter 2).  These results 
suggest that estrogen/estrogen receptor signaling is aberrant in ovarian cancer of the 
hen.  This aberrant signaling may contribute to a variety of downstream effects.  For 
instance, estrogen may play a role in the development and/or progression of specific 
subtypes of ovarian cancer.  We observed that exogenous administration of estrogen 
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resulted in an increased prevalence of serous type tumors compared to control 
treatment, although this did not reach statistical significance (Chapter 3).  
Interestingly, studies have reported that serous ovarian tumors in women are more 
commonly estrogen receptor positive (along with endometrioid tumors) [11] and 
hence may be responsive to estrogen stimulation.  Estrogen has also been shown to 
affect multiple cellular pathways in ovarian cancer cells, including proliferation, 
apoptosis, as well as metastasis and invasion [12].  Figure 5.1 summarizes the possible 
role of estrogen/estrogen receptor signaling in ovarian tumor progression.   
Our studies have yielded information about ovarian tumor development and 
progression in the hen, but there are still questions to be answered.  Future studies in 
the hen should focus on determining the site of origin of ovarian cancer.  It is possible 
that chicken ovarian tumors may develop along two distinct pathways with different 
sites of origin, similar to tumors in women.  These distinct tumor types may exhibit 
different gene mutations, behavior, and response to therapeutics; therefore, 
determining the site of origin would have implications for the diagnosis and treatment 
of ovarian cancer in women.  Our study suggests that the oviduct may be an 
alternative site of origin, but we cannot rule out the possibility of de-differentiation of 
the OSE (Chapter 2).  One way to examine whether ovarian tumors in the hen derive 
from the oviduct would be to study the infundibulum.  In humans, there is an 
association between the presence of tubal intraepithelial carcinomas (TICs) in the 
fallopian tube and serous ovarian carcinoma [13].  In our study (Chapter 3), ovarian 
tumors are frequently accompanied by nodules in the oviduct, but we did not examine 
the infundibulum histologically to determine whether TICs exist.  These studies could 
provide correlative evidence for the oviductal origin of chicken ovarian cancer.   
Direct evidence for an oviduct source of ovarian tumors could be derived from 
studies in which normal oviduct epithelial cells (possibly tagged for visualization) are 
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incorporated into the ovary.  The viability and proliferative capacity of these cells, as 
well as the ability of the cells to embed into the ovarian stroma and respond to steroid 
hormone signals could be monitored.  Ultimately, it would be interesting to see if 
transplanted oviduct epithelial cells can form ovarian tumors, but this ability may be 
dependent on the nature of the transplanted cells.  For instance, oviduct cells that 
exhibit p53 mutations (the “p53 signature”) are proposed to represent the precursor of 
ovarian serous carcinomas [14] and these cells might prove to represent the precursor 
of chicken ovarian tumors as well.  This type of experiment may not definitively 
determine whether chicken ovarian tumors do arise from the oviduct, but it can 
determined whether oviduct epithelial cells have the capacity to survive and thrive in 
the ovarian environment.   
Since we have not ruled out the OSE as a source of chicken ovarian tumors at 
this time, further analysis of chicken OSE can be conducted in parallel.  Studies of 
human ovarian cancer suggest that genetic alterations of the OSE may create a distinct 
population of differentiated cells that undergo metastasis (stochastic model) or a 
cancer stem cell population that initiates tumor development (hierarchical model) 
[reviewed in 15].  There is increasing evidence that cancer initiating cells, or cancer 
stem cells derived from somatic stem cells, may play a role in the initiation of ovarian 
cancer [reviewed in 15] and putative cancer stem cells have been identified in the OSE 
[reviewed in 16].  Furthermore, a recent study has shown that the OSE expresses 
genes associated with adult stem cell maintenance, supporting the idea that these cells 
are multipotent and capable of serving as a precursor for the multiple subtypes of 
ovarian cancer [17].  To date, only one study characterizing chicken OSE has been 
published [18], therefore it is clear that more research is needed to examine the 
possibility of the OSE as a site of origin of chicken ovarian cancer. 
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We have also provided evidence that ovulation is important for the initiation of 
ovarian tumor development (Chapter 3).  Our study design, however, does not allow 
us to separate the effect of ovulation suppression from that of hormones on the 
prevalence of ovarian cancer in the hen.  We have used hormones to decrease egg 
production and cannot rule out a direct effect of these hormones on cellular processes.  
Alternative methods, such as feed restriction or manipulation of photoperiod, can be 
used to decrease ovulatory events and assess the effect of ovulation on the prevalence 
of ovarian cancer.  We also have not determined the mechanism of oral contraceptive 
action in the chicken ovary.  As mentioned previously, administration of progestin in 
monkeys was associated with an increase of apoptosis in the OSE [19], and this has 
been proposed as the mechanism for the protective effect of oral contraceptives. Our 
studies suggest that there is no direct effect of progestin on ovarian cancer prevalence 
since we did not observe an effect on apoptosis in the OSE of hens treated with 
progestin (Chapter 3).  We measured only one indicator of apoptosis (TUNEL), 
however, and did not examine other cellular pathways.  It is possible that progestin 
administration affects other cellular pathways, such as wound healing.  Proper wound 
healing would prevent the accumulation of cells (either from the oviduct or OSE) with 
inflammation-induced mutations.  Interestingly, studies in sheep have shown that 
progesterone plays a role in PARP-mediated DNA repair [20], as well as DNA base 
excision repair [21] at the site of ovulation.  Future studies in the hen are needed to 
determine the effect of progestins on ovarian cancer development.               
Finally, we have provided evidence of a role for estrogen receptor signaling in 
ovarian cancer of the hen (Chapter 4), but it is currently not clear what the 
downstream effects of this signaling are.  Studies could be designed to determine what 
cellular processes and pathways are affected by estrogen in order to identify possible 
therapeutic targets.  For instance, global gene expression analysis could be conducted 
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utilizing the ovarian samples from our in vivo study (Chapter 3).  Estrogen-regulated 
genes could be identified by comparing the ovarian tissue from control hens and those 
treated with estrogen.  Once these genes are identified, they can be tested for 
oncogenic or tumor suppressor effects and the hen could be used to test putative 
therapeutics targeting these genes.  Additional studies could be conducted to examine 
the nature of the estrogen receptor in chicken ovarian tumors.  Estrogen receptors can 
signal through a variety of mechanisms including genomic and non-genomic 
pathways.  Genomic effects are long-lasting and result in the transcription of target 
genes.  Non-genomic pathways are rapid and result in the activation of membrane 
signaling pathways.  Studies in women have shown that estrogen can initiate 
membrane signaling pathways that regulate cell proliferation and prevent apoptosis in 
breast cancer [reviewed in 22].  No studies to date, have examined the role of non-
genomic estrogen signaling in ovarian cancer.  Non-genomic effects are mediated by a 
membrane-associated estrogen receptor, so the cellular localization of the estrogen 
receptor in chicken ovarian tumors could be determined.  If estrogen receptors are 
present on the membrane in tumors, the functionality of these receptors could be tested 
in vitro.  In addition, the rapid responses mediated by estrogen receptor could be 
investigated.  If non-genomic signaling in response to estrogen exists in ovarian 
cancer, these pathways represent other possible therapeutic targets as has been 
proposed for breast cancer [23].   
In conclusion, ovarian cancer is a deadly disease that is only just beginning to 
be better understood.  Studies in the hen can provide valuable information about the 
origin, development, and progression of ovarian cancer that may unlock the mysteries 
of ovarian cancer in women.
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APPENDICES 
 
Appendix 1 Differentially expressed genes between ovarian tissue from hens with 
cancer (n=3) and tissue from normal hens (n=3).  Asterisks indicate oviduct-related 
genes selected for further analysis.  Fold change >1 indicates up-regulated genes and 
fold change <1 indicates down-regulated genes in chicken ovarian tumors compared to 
normal ovary. 
 
Gene ID Gene symbol Gene name Fold 
change 
p-value 
Gga.623.1.S1_at SERPINB14* Ovalbumin (OVAL) 267 0.00199 
Gga.5085.1.S1_at OVM* Ovomucoid (OVM) 223 8.69x10
-5
 
GgaAffx.8146.1.S1_at SERPINB14B* Serpin peptidase inhibitor, clade B 
(ovalbumin), member 3 (SERPINB3) 
134 0.00025 
Gga.5527.1.S1_at TSPAN1 Tetraspanin 1 102 0.00077 
Gga.6723.1.S1_at LOC422031 Similar to meleagrin 74 0.00017 
Gga.8175.1.S1_x_at RAP2B RAP2B, member of RAS oncogene 
family 
71 0.00029 
Gga.7493.1.S1_at  Transcribed locus 69 0.00032 
GgaAffx.7417.1.S1_at LOC428451 Similar to prostatic acid phosphatase 
precursor 
65 0.00219 
Gga.6496.1.S1_at GAL11 Gallicin 11 60 0.00021 
Gga.2952.S1_s_at TF* Transferrin (lactotransferrin; LTF) 51 4.49x10
-5
 
Gga.2982.1.S1_at CLDN3 Claudin 3 46 0.00538 
Gga.2982.1.S1_at CDH1 Cadherin 1, type 1, E-cadherin 
(epithelial) 
40 0.00198 
Gga.125.1.S1_at LOC396449* Riboflavin-binding protein (RD) 39 0.00522 
Gga.6520.1.S1_at KRT20 Keratin 20 37 0.00329 
GgaAffx.3635.1.S1_at LOC427400 Hypothetical LOC427400 36 0.00103 
Gga.5848.3.S1_a_at CLDN10 Claudin 10 35 0.00943 
Gga.713.1.S1_at LYZ Lysozyme (renal amyloidosis) 28 0.00551 
Gga.7931.1.S1_at  Transcribed locus 26 0.00527 
GgaAffx.21785.1.S1_s_at FOXA2 Forkhead box A2 19 0.00182 
GgaAffx.21835.1.S1_s_at GAL12 Beta-defensin 12 18 0.00229 
Gga.4977.1.S1_at MSX2 Msh homeobox 2 16 0.00893 
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Gga.313.1.S1_at PAX2* Paired box 2 16 0.00636 
Gga.7195.1.S1_at CMTM8 CKLF-like MARVEL transmembrane 
domain containing 8 
13 0.00601 
Gga.5856.1.S1_at SLC9A2 Solute carrier family 9 
(sodium/hydrogen exchanger), member 
2 
8 0.00037 
Gga.16523.1.S2_s_at ATP2A3 ATPase, Ca2+ transporting, ubiquitous 8 0.00910 
Gga.7466.1.S1_at FAM123A Family with sequence similarity 123A 8 0.00830 
Gga.2807.1.S1_at  EST,clone ChEST945a6 8 0.00515 
Gga.2739.1.S1_at 
 
 EST,clone ChEST748p24 
 
7 0.00453 
GgaAffx.7428.1.S1_at 
 
ACPP Acid phosphatase, prostate 7 0.00577 
Gga.8264.1.S1_at  Transcribed locus 7 2.41x10-5 
Gga.318.1.S1_at KCNN2 Potassium intermediate/small 
conductance calcium activated channel, 
subfamily N member 2 SK2 
7 0.00154 
Gga.18351.1.A1_at SULF1 Sulfatase 1 7 0.00274 
Gga.19929.1.S1_at  EST,clone ChEST821a11 7 0.00552 
GgaAffx.3636.1.S1_at LOC427400 LOC427400 7 0.00680 
Gga.2072.1.S1_a_at CA8 Carbonic anhydrase 8 6 0.00235 
GgaAffx.9042.3.S1_s_at LOC427942 Similar to alpha-2-macroglobulin 6 0.00615 
GgaAffx.7879.1.S1_at LOC418038 Similar to IP4/PIP3 binding protein-like 
protein 
5 0.00573 
Gga.8064.1.S1_at C9orf150 Chromosome 9 open reading frame 150 5 0.00259 
GgaAffx.12270.1.S1_at ATP13A4 ATPase type 13A4 RCJMB04_11o9 4 0.00296 
GgaAffx.21637.1.S1_s_at HNF1B HNF1 homeobox B 4 0.00981 
GgaAffx.24025.3.S1_at SERPINB1 Serpin peptidase inhibitor, clade B 
(ovalbumin) pseudogene 1 SERPINB11 
4 0.00910 
Gga.12073.1.S1_a_at KRT23 Keratin 23 4 0.00507 
Gga.243.3.S1_a_at NTM Neurotrimin CEPU 4 0.00615 
GgaAffx.20877.1.S1_at SOX7 SRY (sex determining region Y)-box 7  4 0.00093 
Gga.15641.1.S1_at  Transcribed locus 4 0.00796 
Gga.10566.1.S1_at CHRM5 Cholinergic receptor, muscarinic 5 
CHKM5MR  
3 0.00219 
GgaAffx.24029.1.S1_s_at MARVELD3 MARVEL domain containing 3 3 0.00577 
Gga.15371.1.S1_at LOC768772 LOC768772 3 0.00398 
Gga.481.1.S1_at FMOD Fibromodulin 3 0.00887 
Gga.7425.1.S1_at ANXA8 Annexin A8 3 0.00658 
GgaAffx.25068.3.S1_s_at TBC1D8 TBC1 domain family, member 8 3 0.00771 
GgaAffx.1913.1.S1_at HOXB5 Homeobox B5 3 0.00721 
Gga.14878.1.S1_at  EST,clone ChEST289i12 3 0.00978 
Gga.3242.1.S1_at LOC769185 Similar to Breast Carcinoma amplified 
sequence 1 (BCAS1) 
3 0.00154 
Gga.7207.1.S1_at  Transcribed locus 3 0.00910 
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Gga.7777.1.S1_at  Transcribed locus; strongly similar to 
NP_001161383.1 
3 0.00361 
Gga.14691.1.S1_at TUFT1 Tuftelin 1 3 0.00230 
Gga.6096.1.S1_at EPB41L5 Erythrocyte membrane protein band 4.1 
like 5 
3 0.00535 
Gga.5494.1.S1_at CPE Carboxypeptidase E 3 0.00328 
Gga.8076.2.S1_a_at GNAL Guanine nucleotide binding protein (G 
protein), alpha activating activity 
polypeptide, olfactory type  
3 0.00241 
Gga.14228.1.S1_at  EST,clone ChEST496p9 3 0.00706 
Gga.7379.1.S1_at  EST,clone ChEST53p22 3 0.00386 
Gga.4730.1.S1_at NAPB N-methylmaleimide-sensitive factor 
attachment protein, beta 
2 0.00795 
GgaAffx.2745.1.S1_at LUZP2 Leucine zipper protein 2 2 0.00109 
Gga.9994.1.S1_at RNF146 Ring finger protein 146 2 0.00023 
GgaAffx.354.1.S1_at LOC421173 Similar to leucine-rich repeat-containing 
G protein-coupled receptor 6 
2 0.00240 
Gga.12667.1.S1_at FILIP1 Filamin A interacting protein 1 2 0.00837 
Gga.10429.2.S1_a_at  EST, clone ChEST178l15 2 0.00834 
GgaAffx.5710.2.S1_s_at NPDC1 Neural proliferation, differentiation and 
control, 1 
2 0.00341 
Gga.2899.1.S1_at  EST,clone ChEST380f7 2 0.00499 
Gga.9519.1.A1_at LOC420552 Hypothetical gene supported by 
BX929555 
2 0.00420 
Gga.14236.1.S1_at  EST, clone ChEST123g6 2 0.00903 
Gga.10365.1.S1_at  EST, clone ChEST662h4 2 0.00209 
GgaAffx.12013.1.S1_s_at CAT Catalase RCJMB04_1j22 2 0.00447 
GgaAffx.3186.1.S1_at DRD4 Dopamine receptor D4 2 0.00774 
GgaAffx.4323.1.S1_at TMC5 Transmembrane channel-like 5 2 0.00691 
GgaAffx.20372.1.S1_at  EST, clone ChEST915k14 2 1.93x10-5 
GgaAffx.7275.1.S1_at RPS6KA2 Ribosomal protein S6 kinase, 90 kDa, 
polypeptide 2 
2 0.00576 
GgaAffx.8253.1.S1_at CACNA1C Calcium channel, voltage-dependent, L 
type, alpha 1C subunit CHCACHA1C 
2 0.00842 
Gga.8900.1.S1_a_at ZNF711 Zinc finger protein 711 ZNF6 2 0.00022 
GgaAffx.21089.1.S1_at LMO7 Lim domain 7 2 0.00821 
Gga.9403.1.S1_a_at CCDC109B Coiled-coil domain containing 109B 2 0.00130 
Gga.14898.1.S1_at  EST, clone ChEST649o12 2 0.00306 
Gga.12534.1.S1_at LXN Latexin 2 0.00112 
Gga.13321.2.S1_a_at PHB Prohibitin 2 0.00856 
Gga.14559.1.S1_at  EST, clone ChEST47i6 2 0.00048 
GgaAffx.20465.1.S1_at  EST, clone ChEST765p22 2 0.00556 
GgaAffx.25114.3.S1_s_at MBNL2 Muscleblind-like 2 (Drosophila) 2 0.00010 
GgaAffx.1062.1.S1_at CAMKK1 Calcium/calmodulin-dependent protein 
kinase kinase 1, alpha 
2 0.00625 
Gga.15005.1.S1_at  EST, clone ChEST1030n3 2 0.00495 
Gga.5576.2.S1_at LOC770142 Similar to histone H4 2 0.00233 
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GgaAffx.5604.1.S1_at PLCB4 Phospholipase C, beta 4 2 0.00861 
Gga.18457.1.S1_at  EST, clone ChEST629l13 2 0.00649 
Gga.183.1.S1_at UGT8 UDP glycosyltransferase 8 2 0.00207 
Gga.324.1.S1_at LOC395589 Myeloid ectopic viral insertion site-1a 
protein 
2 0.00309 
Gga.8900.2.S1_a_at  EST, clone ChEST984i16 2 0.00991 
Gga.10682.1.S1_at  EST, clone ChEST964e13 2 0.00293 
Gga.2733.1.S1_at CNR1 Cannabinoid receptor 1 (brain) 2 0.00087 
Gga.12356.2.S1_a_at  EST, clone ChEST870g24 2 0.00637 
Gga.15231.1.S1_at C21orf70 Chromosome 21 open reading frame 70 2 0.00617 
Gga.12036.1.S1_at EHF ETS homologous factors 2 5.79x10-5 
GgaAffx.10063.1.S1_at C6orf165 Chromosome 6 open reading frame 165 2 0.00366 
Gga.8542.3.S1_a_at ATP50 ATP synthase, H+ transporting, 
mitochondrial F1 complex, O subunit 
2 0.00573 
GgaAffx.7270.1.S1_at   2 0.00653 
Gga.10212.1.S1_at  EST, clone ChEST1026b10 2 0.00564 
Gga.5218.1.S1_at GKAP1 G kinase anchoring protein 2 0.00336 
GgaAffx.20956.1.S1_at C1orf34 Chromosome 1 open reading frame 34 2 0.00856 
GgaAffx.21665.1.S1_at  EST, clone ChEST743l10 2 0.00459 
GgaAffx.12102.1.S1_s_at PMS1 Postmeiotic segregation increased 1 2 0.00018 
GgaAffx.22140.1.S1_at LOC425659 LOC425659 2 0.00487 
Gga.17189.1.S1_at  EST, clone ChEST536g4 2 0.00786 
GgaAffx.1456.1.S1_at   2 0.00071 
GgaAffx.858.1.S1_s_at ZNF652 Zinc finger protein 652 2 0.00415 
Gga.15876.1.S1_at LRIG3 Leucine-rich repeats and 
immunoglobulin-like domains 3 
2 0.00560 
Gga.12927.1.S1_at DNAJC11 DnaJ (Hsp40) homolog, subfamily C, 
member 11 
2 0.00214 
Gga.17291.1.S1_at C1orf168 Chromosome 1 open reading frame 168 2 0.00503 
GgaAffx.2157.2.S1_s_at CA12 Carbonic anhydrase XII 2 0.00323 
GgaAffx.11083.1.S1_at FGF23 Fibroblast growth factor 23 2 0.00026 
GgaAffx.3994.1.S1_s_at PANK1 Panthothenate kinase 1 2 0.00224 
Gga.979.1.S1_at PCK2 Phosphoenolpyruvate carboxykinase 
PEPCK-M 
2 0.00967 
Gga.279.1.S1_at DTX4 Deltex homolog 4 (Drosophila) 2 0.00304 
Gga.7002.1.S1_at FBXW8 F-box and WD repeat domain containing 
8 
2 0.00684 
GgaAffx.7745.3.S1_s_at PDE1C Phosphodiesterase 1C, calmodulin-
dependent 70 kDa 
2 0.00796 
Gga.10214.1.S1_at MAPK12 Mitogen-activated protein kinase 12 2 0.00029 
GgaAffx.8959.1.S1_s_at TEC Tec protein kinase RCJMB04_29e6 2 0.00504 
Gga.9636.1.S1_at SNORA32 Small nucleolar RNA, H/ACA box 32 
JOSD3 
2 0.00839 
Gga.6364.1.S1_at CDCA7L Cell division cycle associated 7-like 
RCJMB04_35j20 
2 0.00338 
GgaAffx.26459.1.S1_s_at USP54 Ubiquitin specific peptidase 4 2 0.00532 
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GgaAffx.26404.1.S1_at NDST2 N-deacetylase/N-sulfotransferase 
(heparin glucosaminyl) 2 
2 0.00713 
Gga.16148.1.S1_at  Transcribed locus 2 0.00184 
Gga.15463.1.S1_at LOC769636 LOC769636 2 0.00093 
Gga.1743.1.S1_at LOC769944 LOC769944 2 0.00164 
GgaAffx.6654.1.S1_at NRXN3 Neurexin 3 2 0.00171 
GgaAffx.20862.1.S1_s_at PPAP2B Phosphatidic acid phosphatase type 2B 2 0.00492 
GgaAffx.21067.1.S1_at  EST, clone ChEST867d17 2 0.00467 
Gga.5301.1.S1_at FAHD1 Fumarylacetoacetate hydrolase domain 
containing 1 
2 0.00171 
Gga.9005.2.S1_a_at LOC422424 Similar to growth and transformation-
dependent protein 
2 0.00213 
Gga.3136.1.S1_at SDC3 Syndecan 3 2 0.00863 
Gga.10477.1.S1_at TNFRSF19 Tumor necrosis factor receptor 
superfamily, member 19 
2 0.00672 
Gga.6284.2.S1_a_at ECHDC3 Enoyl Coenzyme A hydratase domain 
containing 3 
2 0.00928 
GgaAffx.8204.2.S1_s_at ZBTB2 Zinc finger and BTB domain containing 
2 RCJMB04_22k16 
2 0.00676 
Gga.9292.1.S1_at EIF2AK2 Eukaryotic translation initiation factor 2-
alpha kinase 2 PKR 
2 0.00279 
   EST, clone ChEST321m13 0.66 0.00824 
Gga.1647.1.S1_at  EST, clone ChEST712h12 0.66 0.00557 
Gga.9917.1.S1_at CBLL1 Cas-BR-M (murine) ectopic retroviral 
transforming sequence-like 1 
RCJMB04_31p12 
0.66 0.00648 
GgaAffx.11134.1.S1_at SPSB4 SplaA/ryanodine receptor domain and 
SOCS box containing 4 
0.66 0.00155 
Gga.19160.1.S1_s_at SLC10A7 Solute carrier family 10, member 7 
RCJMB04_18a5 
0.66 0.00212 
GgaAffx.12454.1.S1_s_at PPT1 Palmitoyl-protein thioesterase 1 
RCJMB04_15o4 
0.66 0.00528 
GgaAffx.11537.1.S1_s_at LGTN Ligatin RCJMB04_2e17 0.65 0.00664 
GgaAffx.7884.1.S1_at DDHD1 DDHD domain containing 1 0.65 0.00899 
GgaAffx.1335.2.S1_s_at RNF157 Ring finger protein 157 0.65 0.00083 
Gga.9574.1.S1_at LOC419390 Similar to enhancer of split related 
protein-7 
0.65 0.00152 
Gga.10127.1.S1_at LOC423499 Similar to SERTA domain-containing 
protein 2 
0.65 0.00197 
Gga.14609.1.S1_at HERC4 Hect domain and RLD 4 
RCJMB04_3p16 
0.64 0.00314  
GgaAffx.6768.1.S1_s_at SDCCAG8 Serologically defined colon cancer 
antigen 8 
0.64 0.00499 
Gga.12287.1.S1_at  EST, clone ChEST209e2 0.64 0.00604 
GgaAffx.21118.1.S1_s_at LOC770402 Similar to long microtubule-associated 
protein 1A 
0.63 0.00109 
GgaAffx.12114.1.S1_at HAUS6 HAUS augmin-like complex, subunit 6 
RCJMB04_9g9 
0.63 0.00443 
GgaAffx.12080.1.S1_s_at DCK Deoxycytidine kinase RCJMB04_2e2 0.63 0.00344 
GgaAffx.5670.1.S1_at WNT16 Wingless-type MMTV integration site 
family, member 16 
0.62 0.00853 
Gga.17993.1.S1_at ZC3HAV1 Zinc finger CCCH-type antiviral 1 
RCJMB04_23i8 
0.62 0.00681 
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GgaAffx.11665.1.S1_at ITGA9 Integrin, alpha 9 RCJMB04_3g3 0.62 0.00978 
Gga.11861.1.S1_at TRNT1 tRNA nucleotidyl transferase, CCA-
adding, 1 
0.62 0.00457 
GgaAffx.10761.1.S1_s_at SH3RF3 SH3 domain containing ring finger 3 
SH3MD4 
0.62 0.00490 
GgaAffx.20976.1.S1_at  EST, clone ChEST755g14 0.62 0.00622 
Gga.5528.1.S1_at CTBP2 C-terminal binding protein 2 0.62 0.00565 
Gga.16897.1.S1_at ETAA1 Ewing tumor-associated antigen 1  0.62 0.00185 
Gga.9048.1.S1_at  Transcribed locus 0.62 0.00993 
Gga.7465.1.S1_at  Transcribed locus 0.62 0.00166 
Gga.2498.1.S1_at  EST, clone ChEST730j18 0.61 0.00316 
GgaAffx.5168.2.S1_s_at TRIM36 Tripartite motif-containing 36 0.61 0.00586 
Gga.5692.1.S1_at NDUFB4 NADH dehydrogenase (ubiquinone) 1 
beta subcomplex, 4, 15kDa 
0.61 0.00844 
GgaAffx.11745.1.S1_s_at  BIN1 Bridging integrator 1 RCJMB04_4n21 0.61 0.00245 
GgaAffx.26778.1.A1_s_at   0.61 0.00341 
GgaAffx.21368.1.S1_at NPTN Neuroplastin SDFR1 0.61 0.00258 
GgaAffx.3618.1.A1_at LOC776960 LOC776960 0.61 0.00029 
GgaAffx.24513.9.S1_s_at EPB41L3 Erythrocyte membrane protein band 4.1-
like 3 
0.61 0.00349 
Gga.16540.1.S1_s_at HELLS Helicase, lymphoid specific 
RCJMB04_11c16 
0.61 0.00243 
GgaAffx.9985.1.S1_s_at ROD1 Regulator of differentiation 1 (S. pombe) 0.60 0.00813 
Gga.7965.1.S1_at RAMP3 Receptor (G protein-coupled) activity 
modifying protein 3 
0.60 0.00813 
GgaAffx.20451.1.S1_s_at  EST, clone ChEST905o6 0.59 0.00696 
Gga.13301.1.S1_at GDPD5 Glycerophosphodiester 
phosphodiesterase domain containing 5 
GDE2 
0.59 0.00029 
Gga.249.1.S1_at SLC6A2 Solute carrier family 6, member 2 0.59 0.00585 
GgaAffx.3906.1.S1_s_at GALNS Galactosamine (N-acetyl)-6-sulfate 
sulfatase 
0.59 0.00663 
Gga.9326.2.S1_at LOC768982 LOC768982 0.59 0.00946 
GgaAffx.20545.1.S1_at  EST, clone ChEST1015n20 0.59 0.00646 
GgaAffx.12860.1.S1_at TXNDC5 Thioredoxin domain containing 5 
RCJMB04_24o2 
0.58 0.00274 
GgaAffx.20498.1.S1_s_at MMD Monocyte to macrophage differentiation-
associated RCJMB04_11o17 
0.58 0.00406 
GgaAffx.9461.1.S1_at   0.58 0.00724 
Gga.20014.1.S1_s_at DNER Delta/notch-like EGF repeat containing 0.58 0.00105 
Gga.14884.1.S1_s_at CCDC88A Coiled-coil domain containing 88A 
RCJMB04_18n22 
0.57 0.00423 
Gga.5537.1.S1_at FUNDC1 FUN14 domain containing 1 0.57 0.00632 
GgaAffx.9094.1.S1_s_at RELL1 RELT-like 1 RCJMB04_24l24 0.57 0.00884 
Gga.4724.1.S2_at HSP90B1 Heat shock protein 90kDa beta (Grp94), 
member 1 hsp108 
0.57 0.00183 
Gga.1182.1.S1_s_at MOV10 Mov10, Moloney leukemia virus 10, 
homolog RCJMB04_11i10 
0.57 0.00698 
Gga.20082.1.S1_at  EST, clone ChEST846a5 0.56 0.00801 
 142 
Gga.18136.1.S1_at ZDHHC21 Zinc finger, DHHC-type containing 21 
RCJMB04_10p19 
0.56 0.00637 
GgaAffx.6392.1.S1_at DMRT3 Doublesex and mab-3 related 
transcription factor 3 
0.56 0.00066 
Gga.9228.1.S1_at CAMSAP1L1 Calmodulin regulated spectrin-
associated protein 1-like 1  
0.56 0.00495 
Gga.14837.1.S1_at  EST, clone ChEST14i12 0.56 0.00302 
GgaAffx.1633.1.S1_at BDP1 B double prime 1, subunit of RNA 
polymerase III transcription initiation 
factor IIIB 
0.55 0.00224 
GgaAffx.20969.1.S1_at  EST, clone ChEST322a24 0.55 0.00524 
GgaAffx.20558.1.S1_at CHD1 Chromodomain helicase DNA binding 
protein 1 
0.55 0.00363 
GgaAffx.20217.1.S1_at LOC418900 LOC418900 0.55 0.00691 
Gga.19070.1.S1_s_at  Transcribed locus 0.54 0.00662 
Gga.6321.1.S1_a_at UBE2T Ubiquitin-conjugating enzyme E2T 0.54 0.00716 
GgaAffx.25800.4.S1_at LOC776927 Similar to HBxAg transactivated protein 
2 
0.54 0.00909 
GgaAffx.5271.1.S1_at MAGI2 Membrane associated guanylate kinase, 
WW and PDZ domain containing 2 
0.53 0.00030 
Gga.5416.1.S1_at  EST, clone ChEST601e1 0.53 0.00937 
Gga.12594.1.S1_at LOC424461 Similar to TGF-beta type II receptor 0.53 0.00580 
GgaAffx.5267.1.S1_at LMCD1 LIM and cysteine-rich domains 1 0.53 0.00187 
GgaAffx.22895.1.S1_at EPB41L1 Erythrocyte membrane protein band 4.1-
like 1 
0.52 0.00637 
Gga.475.1.S2_at FSHR Follicle stimulating hormone receptor 0.52 0.00933 
Gga.487.1.S1_at SEMA3A Sema domain, immunoglobulin domain 
(IgG),short basic domain, secreted, 
(semaphoring) 3A 
0.51 0.00228 
Gga.8061.1.S1_at HSCB HscB iron-sulfur cluster co-chaperone 
homolog (E. Coli) 
0.51 0.00654 
Gga.795.1.S1_at GATA4 GATA binding protein 4 GATA-4 0.51 0.00212 
Gga.7011.1.S1_a_at LOC419195 Similar to cAMP-dependent protein 
kinase inhibitor gamma 
0.51 0.00444 
Gga.18592.1.S1_at  EST, clone ChEST194e10 0.51 0.00191 
GgaAffx.7674.1.S1_at AOAH Acyloxyacyl hydrolase (neutrophil) 0.51 0.00032 
GgaAffx.25748.2.S1_s_at COL4A3 Collagen, type IV, alpha 3 0.51 0.00868 
GgaAffx.7149.1.S1_at PLCL2 Phospholipase C-like 2 0.50 0.00764 
Gga.8200.1.S1_s_at SLC16A10 Solute carrier family 16, member 10  0.50 0.00337 
Gga.19591.1.S1_at LOC428770 Prematurely terminated mRNA decay 
factor-like 
0.50 0.00757 
GgaAffx.21823.1.S1_s_at LOC414835 cHz-cadherin 0.50 0.00638 
Gga.12991.1.S1_at  EST, clone ChEST397k15 0.49 0.00892 
Gga.15184.1.S1_at  EST, clone ChEST843h5 0.49 0.00925 
Gga.8510.1.S1_at  Transcribed locus, strongly similar to 
NP_009016.1 
0.49 0.00936 
Gga.18929.1.S1_s_at WIPF1 WAS/WASL interacting protein family, 
member 1 RCJMB04_9m19 WASPIP 
0.48 0.00638 
GgaAffx.12599.1.S1_s_at TMEM68 Transmembrane protein 68 
RCJMB04_19b17 
0.48 0.00115 
GgaAffx.12419.1.S1_s_at DTL Denticleless homolog (Drosophila) 
RCJMB04_15a2 
0.47 0.00863 
 143 
Gga.8786.1.S1_at LGR4 Leucine-rich repeat-containing G 
protein-coupled receptor 4 
0.46 0.00105 
Gga.4505.1.S2_at MYBL1 Myeloblastosis oncogene-like 1 0.45 0.00543 
GgaAffx.6177.1.S1_at GNS Glucosamine (N-acetyl)-6-sulfatase 0.44 0.00304 
Gga.15893.1.S1_at  EST, clone ChEST114c13 0.44 0.00102 
GgaAffx.5110.6.S1_s_at COL4A5 Collagen, type IV, alpha 5 0.43 0.00489 
GgaAffx.11375.1.S1_at MTSS1 Metastasis suppressor 1 RCJMB04_1a13 0.43 0.00820 
Gga.10375.1.S1_at KCNK9 Potassium channel, subfamily K, 
member 9 KCNK3 
0.42 0.00457 
Gga.13092.1.S1_at  EST, clone ChEST254e9 0.42 0.00091 
Gga.13341.1.S1_at PLEKHH1 Pleckstrin homology domain containing, 
family H, member 1 
0.42 0.00137 
Gga.16573.1.S1_at  EST, clone ChEST537d16 0.42 0.00110 
Gga.4583.2.S1_x_at RPL24 Ribosomal protein L24 0.42 0.00862 
GgaAffx.12513.1.S1_s_at DCTD dCMP deaminase RCJMB04_17c11 0.41 0.00915 
Gga.1964.1.S1_s_at MYO10 Myosin X 0.40 0.00069 
GgaAffx.8024.1.S1_at LOC771624 LOC771624 OCC-1 0.40 0.00340 
GgaAffx.6079.2.S1_s_at KCNK2 Potassium channel, subfamily K, 
member 2 
0.39 0.00585 
Gga.5883.1.S1_at PARP8 Poly (ADP-ribose) polymerase family, 
member 8 
0.39 0.00724 
Gga.17311.1.S1_at  EST, clone ChEST604k23 0.35 0.00298 
Gga.6379.4.S1_a_at CEL Carboxyl ester lipase (bile salt-
stimulated lipase)  
0.35 0.00072 
Gga.195.1.S1_at GPR149 G protein-coupled receptor 149 0.32 0.00162 
Gga.8880.1.S1_at MME Membrane metallo-endopeptidase 0.31 0.00630 
Gga.1530.1.S1_at  Transcribed locus 0.27 0.00958 
Gga.9239.1.S1_s_at LOC768350 MHC-like class 1 Y 0.20 0.00494 
Gga.10425.S1_s_at VSNL1 Visinin-like 1 0.20 0.00056 
Gga.14454.1.S1_at ZPD Zona pellucida protein D 0.19 0.00152 
Gga.7210.1.S1_at ZP3 Zona pellucida glycoprotein 3 (sperm 
receptor) ZPC 
0.09 0.00247 
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Appendix 2  Immunohistochemistry with PAX2 antibody.  Nuclear PAX2 protein 
expression in chicken oviduct (A).  No PAX2 protein expression in the control 
section (B).  Paraffin embedded sections of oviduct (n=3) were boiled in citrate 
buffer for antigen retrieval and blocked in 10% goat serum in PBS for 30 min.  
Sections were then incubated with rabbit anti-human PAX2 (Abcam, Cambridge, 
MA) at a dilution of 1:50 overnight at 4°.  Control slides were incubated without 
primary antibody.  This was followed by incubation in AlexaFluor 488 goat anti-
rabbit IgG (0.24 ug/ml) for 1h at 39°.  Slides were viewed using a Nikon eclipse 
E600 and pictures were taken with a Spot RT Slider camera.  Scale bar = 100 um. 
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Appendix 3A Cell morphology, cellular development, and embryonic development 
pathway created by the Ingenuity Pathway Analysis (IPA) program.  Green indicates 
genes that are up-regulated and red indicates genes that are down-regulated in chicken 
ovarian tumors compared to normal ovary. 
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Appendix 3B Amino acid metabolism, behavior, cell-to-cell signaling, and interaction 
pathway created by the Ingenuity Pathway Analysis (IPA) program.  Green indicates 
genes that are up-regulated and red indicates genes that are down-regulated in chicken 
ovarian tumors compared to normal ovary. 
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Appendix 3C Carbohydrate metabolism, molecular transport and small molecule 
biochemistry pathway created by the Ingenuity Pathway Analysis (IPA) program.  
Green indicates genes that are up-regulated and red indicates genes that are down-
regulated in chicken ovarian tumors compared to normal ovary. 
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Appendix 3D Cell signaling, cellular function and maintenance, and molecular 
transport pathway created by the Ingenuity Pathway Analysis (IPA) program.  Green 
indicates genes that are up-regulated and red indicates genes that are down-regulated 
in chicken ovarian tumors compared to normal ovary. 
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Appendix 3E Cell death, cancer, and developmental disorder pathway created by the 
Ingenuity Pathway Analysis (IPA) program.  Green indicates genes that are up-
regulated and red indicates genes that are down-regulated in chicken ovarian tumors 
compared to normal ovary. 
 
